0001804591-24-000059 | 10-Q | XBRL Viewer

Print Document

Fair Value Measurements	6 Months Ended
Fair Value Measurements	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Recurring Fair Value Measurements The fair value of cash, restricted cash, accounts receivable, accounts payable, and accrued liabilities are stated at their carrying value, which approximates fair value due to the short time to the expected receipt or payment date as of September 30, 2024 and March 31, 2024. Cash equivalents consist primarily of money market funds and are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets. As of September 30, 2024 and March 31, 2024, the Company had $121.0 million and $211.0 million, respectively, held in money market funds. The Company had no transfers between levels of the fair value hierarchy of its assets and liabilities measured at fair value during the six months ended September 30, 2024 and the fiscal year ended March 31, 2024. Nonrecurring Fair Value Measurements Identifiable assets and liabilities acquired or assumed are measured separately at their fair values as of the acquisition date. Certain of the Company’s assets, including intangible assets, are measured at fair value on a nonrecurring basis and are classified in Level 3 of the fair value hierarchy. No nonrecurring fair value measurements were required during the three and six months ended September 30, 2024 and 2023.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 107
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-107

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 940
-SubTopic 820
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478119/940-820-50-1

+ Details

Income Taxes	6 Months Ended
Income Taxes	Sep. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company computes the provision for income taxes by applying the estimated annual effective tax rate to year-to-date income from recurring operations and adjusts the provision for discrete tax items recorded in the period. The Company’s annual estimated effective tax rate differs from the U.S. federal statutory rate primarily as a result of a valuation allowance against its deferred tax assets. An immaterial tax benefit was recognized for the three and six months ended September 30, 2024, and an immaterial tax provision was recognized for the three and six months ended September 30, 2023. The provision tax expense or benefit from income taxes is reflected on the condensed consolidated statements of operations and comprehensive loss for the periods. The Company continues to maintain a full valuation allowance on the remaining net deferred tax assets of the U.S. entities as it is more likely than not that the Company will not realize the deferred tax assets. Utilization of net operating loss carryforwards may be subject to future annual limitations provided by Section 382 of the Code and similar state provisions. The Company files income tax returns in the U.S. federal jurisdiction and various states. As of the date of this filing, the Company is not currently under examination by income tax authorities in federal, state, or other jurisdictions. All tax returns will remain open for examination by the federal and state authorities for three and four years, respectively, from the date of utilization of any net operating loss or credits.

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details

Balance Sheet Components - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Property, Plant and Equipment [Line Items]
Depreciation and amortization expense	$ 2,000,000.0	$ 3,000,000	$ 4,000,000.0	$ 6,000,000.0
Impairment to property and equipment	0	0	0	0
Amortization expense for intangible assets	2,000,000.0	3,800,000	4,000,000.0	7,700,000
Impairment of intangible assets	0	0	0	0
Internal Use Software
Property, Plant and Equipment [Line Items]
Capitalized of internal use software	3,200,000	3,400,000	4,500,000	6,800,000
Internal-use software write-off		1,100,000
Amortization of internal use software	1,600,000	1,300,000	3,400,000	2,500,000
Capitalized computer software, impairment	$ 1,200,000	$ 0	$ 1,200,000	$ 0

Restructuring - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 2,242	$ 2,654	$ 2,242	$ 6,871
Employee Severance
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 1,900	$ 2,700	$ 1,900	$ 6,300

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

Condensed Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)
$ in Thousands

Total

Annual Incentive Plan

Common Stock

A&R Plan

Common Stock

Annual Incentive Plan

Additional Paid-In Capital

^[1]

Additional Paid-In Capital

Annual Incentive Plan

^[1]

Accumulated Other Comprehensive Income (Loss)

Accumulated Deficit

Beginning balance, shares (in shares) at Mar. 31, 2023

^[1]

23,059,998

Beginning balance at Mar. 31, 2023

$ 713,939

$ 2

^[1]

$ 2,220,941

$ (620)

$ (1,506,384)

Issuance of common stock upon exercise of stock options (in shares)

^[1]

9,036

Issuance of common stock upon exercise of stock options

Issuance of common stock upon release of restricted stock units under the 23andMe Second Amended and Restated Annual Incentive Plan (in shares)

^[1]

90,640

448,053

Issuance of common stock upon release of restricted stock units under the 23andMe Second Amended and Restated Annual Incentive Plan

$ 18,630

Net share settlements for stock-based minimum tax withholdings (in shares)

^[1]

(2,949)

Net share settlements for stock-based minimum tax withholdings

(121)

Stock-based compensation expense

47,915

Other comprehensive (loss) income

(334)

Net loss

(104,624)

Ending balance, shares (in shares) at Jun. 30, 2023

^[1]

23,604,778

Ending balance at Jun. 30, 2023

675,490

$ 2

^[1]

2,287,450

(954)

(1,611,008)

Beginning balance, shares (in shares) at Mar. 31, 2023

^[1]

23,059,998

Beginning balance at Mar. 31, 2023

713,939

$ 2

^[1]

2,220,941

(620)

(1,506,384)

Other comprehensive (loss) income

620

Net loss

(179,894)

Ending balance, shares (in shares) at Sep. 30, 2023

^[1]

23,941,551

Ending balance at Sep. 30, 2023

625,251

$ 2

^[1]

2,311,527

(1,686,278)

Beginning balance, shares (in shares) at Jun. 30, 2023

^[1]

23,604,778

Beginning balance at Jun. 30, 2023

675,490

$ 2

^[1]

2,287,450

(954)

(1,611,008)

Issuance of common stock upon exercise of stock options (in shares)

^[1]

41,428

Issuance of common stock upon exercise of stock options

388

Issuance of common stock upon release of restricted stock units under the 23andMe Second Amended and Restated Annual Incentive Plan (in shares)

^[1]

217,919

2,900

Issuance of common stock upon release of restricted stock units under the 23andMe Second Amended and Restated Annual Incentive Plan

102

Net share settlements for stock-based minimum tax withholdings (in shares)

^[1]

(951)

Net share settlements for stock-based minimum tax withholdings

(22)

Issuance of common stock under employee stock purchase plan (in shares)

^[1]

75,477

Issuance of common stock under employee stock purchase plan

1,411

Stock-based compensation expense

22,198

Other comprehensive (loss) income

954

Net loss

(75,270)

Ending balance, shares (in shares) at Sep. 30, 2023

^[1]

23,941,551

Ending balance at Sep. 30, 2023

625,251

$ 2

^[1]

2,311,527

$ 0

(1,686,278)

Beginning balance, shares (in shares) at Mar. 31, 2024

^[1]

24,505,970

Beginning balance at Mar. 31, 2024

188,520

$ 2

^[1]

2,361,606

(2,173,088)

Issuance of common stock upon exercise of stock options (in shares)

^[1]

6,889

Issuance of common stock upon exercise of stock options

Issuance of common stock upon release of restricted stock units under the 23andMe Second Amended and Restated Annual Incentive Plan (in shares)

^[1]

184,838

607,222

Issuance of common stock upon release of restricted stock units under the 23andMe Second Amended and Restated Annual Incentive Plan

$ 6,451

$ 1

^[1]

$ 6,450

Net share settlements for stock-based minimum tax withholdings (in shares)

^[1]

(4,415)

Net share settlements for stock-based minimum tax withholdings

(48)

Stock-based compensation expense

17,923

Net loss

(69,400)

Ending balance, shares (in shares) at Jun. 30, 2024

^[1]

25,300,504

Ending balance at Jun. 30, 2024

143,504

$ 3

^[1]

2,385,989

(2,242,488)

Beginning balance, shares (in shares) at Mar. 31, 2024

^[1]

24,505,970

Beginning balance at Mar. 31, 2024

188,520

$ 2

^[1]

2,361,606

(2,173,088)

Other comprehensive (loss) income

Net loss

(128,503)

Ending balance, shares (in shares) at Sep. 30, 2024

^[1]

25,836,364

Ending balance at Sep. 30, 2024

101,929

$ 3

^[1]

2,403,517

(2,301,591)

Beginning balance, shares (in shares) at Jun. 30, 2024

^[1]

25,300,504

Beginning balance at Jun. 30, 2024

143,504

$ 3

^[1]

2,385,989

(2,242,488)

Issuance of common stock upon release of restricted stock units under the 23andMe Second Amended and Restated Annual Incentive Plan (in shares)

^[1]

484,051

Net share settlements for stock-based minimum tax withholdings (in shares)

^[1]

(9,998)

Net share settlements for stock-based minimum tax withholdings

(70)

Issuance of common stock under employee stock purchase plan (in shares)

^[1]

61,807

Issuance of common stock under employee stock purchase plan

331

Stock-based compensation expense

17,267

Other comprehensive (loss) income

Net loss

(59,103)

Ending balance, shares (in shares) at Sep. 30, 2024

^[1]

25,836,364

Ending balance at Sep. 30, 2024

$ 101,929

$ 3

^[1]

$ 2,403,517

$ (2,301,591)

[1]	Amounts have been adjusted to reflect the reverse stock split that became effective on October 16, 2024. Refer to Note 2, “Summary of Significant Accounting Policies” and Note 19, “Subsequent Events,” for further information about the reverse stock split.

Equity Incentive Plans and Stock-Based Compensation

6 Months Ended

Sep. 30, 2024

Share-Based Payment Arrangement [Abstract]

Equity Incentive Plans and Stock-Based Compensation

Incentive Equity Plans

On September 6, 2023 (the “Effective Date”), the Company’s stockholders approved an amendment and restatement of the 23andMe Holding Co. 2021 Incentive Equity Plan (the “2021 Plan” and, as amended and restated, the “A&R Plan”). The terms of the A&R Plan replaced the existing terms of the 2021 Plan.

As a result of the Reverse Stock Split, on October 16, 2024, the Company amended and restated the A&R Plan, to reflect, pursuant to the provisions of Sections 4(e) and 17(a) thereof, the proportionate adjustment of the number of shares of Company’s Class A common stock authorized and available for issuance under the A&R Plan to 10,034,656 shares using the same one-for-twenty ratio used to consummate the Reverse Stock Split (the “Second A&R Plan”). Additionally, the maximum number of shares of Class A common stock that remained available for issuance pursuant to Incentive Stock Options (“ISO”) under the A&R Plan as of the effective time of the Reverse Stock Split was proportionally adjusted .

In connection with such amendment, pursuant to Section 4(e) of the A&R Plan, the Company’s Board of Directors proportionally adjusted the number of shares of Class A common stock subject to outstanding awards granted pursuant to the A&R Plan and the exercise price per share of Class A common stock of each such award to reflect the impact of the Reverse Stock Split. The impact of the Reverse Stock Split has been applied retroactively to all disclosures.

Pursuant to the Second A&R Plan, the aggregate number of shares of Class A common stock that may be issued or transferred under the Second A&R Plan shall be increased on an annual basis by a number equal to (x) 5.0% of the aggregate number of shares of Class A common stock and Class B common stock, taken together, outstanding as of the last day of the immediately preceding calendar year or (y) such lesser number of shares of Class A common stock as may be determined by the Compensation Committee of the Company’s Board of Directors. Under the Second A&R Plan, options (including non-statutory options and ISO), stock appreciation rights, restricted stock, RSUs, and other stock-based awards may be granted to employees, non-employee directors and certain consultants and advisors of the Company and its subsidiaries. Options have a contractual life of up to ten years. The exercise price of a stock option shall not be less than 100% of the estimated fair value of the shares on the date of grant, as determined by the Board of Directors. For ISO as defined in the Internal Revenue Code of 1986, as amended (the “Code”), the exercise price of an ISO granted to a 10% stockholder shall not be less than 110% of the estimated fair value of the underlying stock on the date of grant as

determined by the Board of Directors. The Company’s options generally vest over three to four years. Under the Second A&R Plan, stock option awards entitle the holder to receive one share of Class A common stock for every option exercised.

Time-based RSUs granted pursuant to the Second A&R Plan generally vest ratably over a period ranging from one to four years and are subject to the participant’s continuing service to the Company over that period. RSUs issued pursuant to the 23andMe Second Amended and Restated Annual Incentive Plan (the “AIP”) upon the achievement of certain pre-determined annual performance metrics, as discussed below, vest immediately upon issuance. Until vested, RSUs do not have the voting and dividend participation rights of Class A common stock and the shares of Class A common stock underlying the awards are not considered issued and outstanding.

The Company issues new shares of Class A common stock upon the exercise of stock options, the vesting and settlement of RSUs, and the issuance of shares purchased under the ESPP (as defined below).

In February 2022, the Compensation Committee of the Company’s Board of Directors adopted a RSU conversion and deferral program for non-employee directors. The purpose of the program is to provide non-employee directors with the option to convert all or a portion of their cash compensation into a RSU award under the Second A&R Plan and the opportunity to defer settlement of all or a portion of their RSU awards. In connection with the Resignations, the Company released all prior deferred RSU awards for the two non-employee directors who elected to defer settlement of their RSU awards. As of September 30, 2024, there were no non-employee directors eligible to participate in the program.

On June 9, 2022, the Compensation Committee of the Company’s Board of Directors adopted the AIP, pursuant to which, beginning in fiscal 2023, employees and certain service providers of 23andMe, Inc. and its affiliates were eligible to receive annual incentive bonuses in the form of cash or RSUs issued by the Company under the Second A&R Plan, based upon the Company’s achievement of certain pre-established financial, operational, and/or strategic performance metrics. On June 3, 2024, the Company paid annual incentive bonuses in the form of RSUs based upon the Company’s achievement of certain pre-established performance metrics during the one-year performance period ended March 31, 2024 and as determined by the Compensation Committee of the Company’s Board of Directors. The number of RSUs granted was determined by dividing the dollar amount of the AIP annual incentive bonuses by the trailing average closing price of the Company’s Class A common stock for the 20 trading days preceding the date of payment resulting in the grant of 607,222 shares underlying fully-vested RSUs on June 5, 2024.

The Company accounts for the RSUs issued under the AIP (the “AIP RSUs”) as liability awards, and adjusts the liability and corresponding expenses at the end of each quarter until the date of settlement, considering the probability that the performance conditions will be satisfied. The Company recorded stock-based compensation expense of $2.9 million and $2.4 million related to the AIP RSUs for the three months ended September 30, 2024 and 2023, respectively, and $7.0 million and $6.8 million for the six months ended September 30, 2024 and 2023, respectively. As of September 30, 2024 and March 31, 2024, the liability of the AIP RSUs was $7.0 million and $6.5 million, respectively, which was included in other current liabilities on the condensed consolidated balance sheet.

Stock Option Activity

Stock option activity and activity regarding shares available for grant under the Second A&R Plan are as follows:


	Options Outstanding
	Outstanding Stock Options	Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value

	(in thousands, except share, years, and per share data)
Balance as of March 31, 2024	3,537,668	$	73.62	5.1	$	306
Granted	88,615	$	6.82
Exercised	(6,889)	$	8.46
Canceled/forfeited/expired	(484,544)	$	86.04
Balance as of September 30, 2024	3,134,850	$	69.95	5.0	$	43
Vested and exercisable as of September 30, 2024	2,457,428	$	78.52	4.1	$	31

The weighted average grant date fair value per share of options granted was $4.61 and $17.40 for the six months ended September 30, 2024 and 2023, respectively. The total intrinsic value of vested options exercised for the six months

ended September 30, 2024 and 2023 was immaterial and $1.0 million, respectively. As of September 30, 2024, unrecognized stock-based compensation expense related to unvested stock options was $17.4 million, which is expected to be recognized over a weighted-average period of 2.1 years. Due to a valuation allowance on deferred tax assets, the Company did not recognize any tax expense or benefit from stock option exercises for the three and six months ended September 30, 2024 and 2023.

The Company estimated the fair value of options granted using the Black-Scholes option-pricing model. The fair value of stock options is being amortized on a straight-line basis over the requisite service period of the awards.

The weighted average Black-Scholes assumptions used to value stock options at the grant dates are as follows:


	Three Months Ended September 30,								Six Months Ended September 30,
	2024				2023				2024				2023
	Min		Max		Min		Max		Min		Max		Min		Max
Expected term (years)	6.0		6.0		5.8		6.0		6.0		6.0		5.8		6.0
Expected volatility range	75	%	75	%	78	%	79	%	75	%	75	%	78	%	79	%
Expected weighted-average volatility	75%				79%				75%				79%
Risk-free interest rate	3.5	%	3.5	%	4.4	%	4.4	%	3.5	%	3.5	%	3.6	%	4.4	%
Expected dividend yield	—		—		—		—		—		—		—		—

Restricted Stock Units

The following table summarizes the RSU activity under the equity incentive plans and related information:


	Unvested RSUs	Weighted-Average Grant Date Fair Value Per Share
Balance as of March 31, 2024	2,203,078	$	45.86
Granted	3,070,895	$	9.36
Vested	(1,276,111)	$	26.41
Canceled/forfeited	(595,865)	$	22.24
Balance as of September 30, 2024	3,401,997	$	24.34

As of September 30, 2024, unrecognized stock-based compensation expense related to outstanding unvested RSUs was $73.6 million, which is expected to be recognized over a weighted-average period of 2.4 years.

Stock Subject to Vesting

In November 2021, in connection with the acquisition of Lemonaid Health ( the “Lemonaid Acquisition”), the Company granted 187,352 shares of Class A common stock with an aggregate grant date fair value of $43.9 million to two recipients, each of whom was a former stockholder and officer of Lemonaid Health (each, a “Former Lemonaid Officer”) and each of whom, following the closing of the Lemonaid Acquisition, joined the Company’s management team. The shares were scheduled to vest over a four-year period in quarterly installments beginning on February 1, 2022, subject to the respective recipient’s continued employment with the Company. In connection with the Lemonaid Acquisition, each of these recipients entered into a relinquishment agreement that provides that during the four-year period that commenced on November 1, 2021 (the “Protection Period”), the Company will not (i) terminate the recipient’s employment without cause, (ii) materially reduce the recipient’s base salary or the benefits to which similarly-situated executive employees of the Company or the Company’s subsidiaries are entitled, other than a broad-based reduction to the same extent that applies to such similarly-situated executive employees, or (iii) relocate the recipient’s principal place of employment to a location outside of a 50-mile radius of their current principal place of employment. If any such event occurs during the Protection Period or in the event of the recipient’s death or disability, then the unvested portion(s) of these awards will immediately vest.

On June 30, 2023, the employment of one of the Former Lemonaid Officers terminated, which resulted in $22.0 million of stock-based compensation expense related to these awards recognized within general and administrative expenses within the condensed consolidated statement of operations.

The Company recognized total stock-based compensation expense related to these awards of $0.4 million and $25.1 million for the three and six months ended September 30, 2023, respectively, within general and administrative expenses. There was no stock-based compensation expense related to these awards recognized during the three and six months ended September 30, 2024. As of September 30, 2024, there was no remaining unamortized stock-based compensation expense associated with these awards.

Employee Stock Purchase Plan

On June 10, 2021, the shareholders of VGAC approved the 23andMe Holding Co. Employee Stock Purchase Plan (“ESPP”). As a result of the Reverse Stock Split, on October 16, 2024, the Company amended and restated the ESPP, to reflect, pursuant to the provisions of Sections III.C and X thereof, the proportionate adjustment of the number of shares of Company’s Class A common stock authorized and available for issuance under the ESPP to 580,456 shares using the same one-for-twenty ratio used to consummate the Reverse Stock Split (the “A&R ESPP”). Additionally, Section III.B of the ESPP, which provides for the automatic annual increase in the number of shares available for issuance under the ESPP, was revised to make proportionate adjustments to reflect the Reverse Stock Split. Accordingly, the number of shares of the Company’s Class A common stock reserved for issuance will automatically increase on January 1 of each calendar year, beginning on January 1, 2025, by the lesser of (i) an amount equal to one percent (1.0%) of the total number of shares of Class A and Class B common stock outstanding as of the last day of the immediately preceding December 31st, (ii) 250,000 shares, or (iii) a lesser number of shares as determined by the Board of Directors in its discretion. No other material modifications or amendments were made to the ESPP.

In connection with such amendment, pursuant to Section III.C of the ESPP, the Company’s Board of Directors also proportionally adjusted the maximum number of shares of Class A common stock purchasable per ESPP participant during any offering period and on any one purchase date during that offering period, the number of shares in effect under each outstanding purchase right, the number of shares issued and to be issued under the ESPP, and the price per share in effect under each outstanding purchase right to reflect the impact of the Reverse Stock Split.

The A&R ESPP provides for concurrent 12-month offerings with successive six-month purchase intervals commencing on March 1 and September 1 of each year and purchase dates occurring on the last day of each such purchase interval (i.e., August 31 and February 28). The A&R ESPP contains a rollover provision whereby if the price of the Company’s Class A common stock on the first day of a new offering period is less than the price on the first day of any preceding offering period, all participants in a preceding offering period with a higher first day price will be automatically withdrawn from such preceding offering period and re-enrolled in the new offering period. The rollover feature, when triggered, will be accounted for as a modification to the preceding offering period, resulting in incremental expense to be recognized over the new offering period.

The Company estimated the fair value of the shares issued pursuant to the A&R ESPP using the Black-Scholes option-pricing model. The fair value is amortized on a straight-line basis over the requisite service period, which is the withholding period. During the six months ended September 30, 2024 and 2023, 61,807 and 75,472 shares of the

Company’s Class A common stock, respectively, were purchased under the A&R ESPP, at an average exercise price of $5.35 and $18.70, respectively.

The per share weighted average grant date fair value of shares issued pursuant to the A&R ESPP for the six months ended September 30, 2024 and 2023 was $2.52 and $8.78, respectively, using the following assumptions:


	Three Months Ended September 30,								Six Months Ended September 30,
	2024				2023				2024				2023
	Min		Max		Min		Max		Min		Max		Min		Max
Expected term (years)	0.5		1.0		0.5		1.0		0.5		1.0		0.5		1.0
Expected volatility	76	%	77	%	67	%	73	%	76	%	77	%	67	%	73	%
Expected weighted-average volatility	76%				70%				76%				70%
Risk-free interest rate	4.4	%	4.8	%	5.4	%	5.5	%	4.4	%	4.8	%	5.4	%	5.5	%
Expected dividend yield	—		—		—		—		—		—		—		—

Stock-Based Compensation

Total stock-based compensation expense, including stock-based compensation expense related to awards classified as liabilities, was included in costs and expenses as follows:


	Three Months Ended September 30,				Six Months Ended September 30,
	2024		2023		2024		2023
	(in thousands)
Cost of service revenue	$	871	$	1,041	$	1,847	$	3,099
Cost of product revenue	442		456		835		870
Research and development	8,565		10,938		19,636		22,630
Sales and marketing	2,155		2,016		4,614		3,734
General and administrative (1)	7,150		9,290		13,828		43,866
Restructuring and other charges	303		—		303		641
Total stock-based compensation expense	$	19,486	$	23,741	$	41,063	$	74,840

(1)Includes $22.0 million of stock-based compensation charges related to the termination of a Former Lemonaid Officer during the six months ended September 30, 2023.

Balance Sheet Components - Operating Lease Right-of-Use Assets, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Mar. 31, 2024
Regulated Operations [Abstract]
Operating lease right-of-use assets	$ 85,166	$ 85,166
Less: accumulated amortization	(40,062)	(36,272)
Operating lease right-of-use assets	$ 45,104	$ 48,894

Balance Sheet Components (Tables)

6 Months Ended

Sep. 30, 2024

Balance Sheet Related Disclosures [Abstract]

Schedule of Prepaid Expense and Other Current Assets

Prepaid expense and other current assets consisted of the following:


	September 30, 2024		March 31, 2024
	(in thousands)
Prepaid expenses	$	12,894	$	9,296
Insurance recovery receivable	22,633		2,188
Other receivables	1,751		3,563
Other current assets	2,372		1,794
Prepaid expenses and other current assets	$	39,650	$	16,841

Schedule of Property and Equipment, Net

Property and equipment, net consisted of the following:


	September 30, 2024		March 31, 2024
	(in thousands)
Computer equipment and software	$	7,392	$	7,485
Laboratory equipment and software	51,363		51,635
Furniture and office equipment	8,937		8,929
Leasehold improvements	41,467		41,180
Capitalized asset retirement obligations	853		853
Property and equipment, gross	110,012		110,082
Less: accumulated depreciation and amortization	(85,198)		(81,731)
Property and equipment, net	$	24,814	$	28,351

Schedule of Lessee Operating Lease, Right-of-Use Asset

Operating lease right-of-use assets, net consisted of the following:


	September 30, 2024		March 31, 2024
	(in thousands)
Operating lease right-of-use assets	$	85,166	$	85,166
Less: accumulated amortization	(40,062)		(36,272)
Operating lease right-of-use assets, net	$	45,104	$	48,894

Schedule of Internal Use Software

Internal-use software, net consisted of the following:


	September 30, 2024		March 31, 2024
	(in thousands)
Capitalized internal-use software	$	39,296	$	35,918
Less: accumulated amortization	(18,817)		(15,402)
Internal-use software, net	$	20,479	$	20,516

Schedule of Intangible Assets, Net

Intangible assets, net consisted of the following:


	September 30, 2024
	Weighted Average Remaining Useful Life (Years)	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
	(in thousands, except years)
Customer relationships	0.0	$	14,900	$	(14,900)	$	—
Partnerships	7.1	9,000		(2,625)		6,375
Trademark	2.1	11,000		(6,417)		4,583
Developed technology	4.1	24,100		(10,042)		14,058
Non-compete agreements	2.1	2,800		(1,633)		1,167
Patents	4.0	5,500		(2,388)		3,112
Total intangible assets		$	67,300	$	(38,005)	$	29,295


	March 31, 2024
	Weighted Average Remaining Useful Life (Years)	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
	(in thousands, except years)
Customer relationships	0.0	$	14,900	$	(14,900)	$	—
Partnerships	7.6	9,000		(2,175)		6,825
Trademark	2.6	11,000		(5,317)		5,683
Developed technology	4.6	24,100		(8,320)		15,780
Non-compete agreements	2.6	2,800		(1,353)		1,447
Patents	4.5	5,500		(1,980)		3,520
Total intangible assets		$	67,300	$	(34,045)	$	33,255

Schedule of Amortization Expense of the Identified Intangible Assets

Estimated future amortization expense of the identified intangible assets as of September 30, 2024 was as follows:


	Estimated Amortization
	(in thousands)
Fiscal years ending March 31,
Remainder of 2025 (Remaining six months)	$	3,960
2026	7,919
2027	6,769
2028	5,006
2029	3,175
Thereafter	2,466
Total estimated future amortization expense	$	29,295

Schedule of Accrued Expense and Other Current Liabilities

Accrued expense and other current liabilities consisted of the following:


	September 30, 2024		March 31, 2024
	(in thousands)
Accrued payables	$	8,660	$	9,697
Accrued settlement and legal expenses	34,525		3,260
Accrued compensation and benefits	3,235		4,266
Accrued vacation	6,643		7,221
Accrued bonus	7,696		7,420
Accrued clinical expenses	5,467		9,291
Accrued taxes and other	1,102		1,108
Total accrued expenses and other current liabilities	$	67,328	$	42,263

Equity Incentive Plans and Stock-Based Compensation - Schedule of Stock Option Activity and Activity Regarding Shares Available for Grant (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Sep. 30, 2024	Mar. 31, 2024
Outstanding Stock Options
Balance, beginning of period (in shares)	3,536,989
Balance, end of period (in shares)	3,134,850	3,536,989
Second A And R Plan
Outstanding Stock Options
Balance, beginning of period (in shares)	3,537,668
Granted (in shares)	88,615
Exercised (in shares)	(6,889)
Cancelled/forfeited/expired (in shares)	(484,544)
Balance, end of period (in shares)	3,134,850	3,537,668
Vested and exercisable as of end of period (in shares)	2,457,428
Weighted-Average Exercise Price
Balance, beginning of period (in usd per share)	$ 73.62
Granted (in usd per share)	6.82
Exercised (in usd per share)	8.46
Cancelled/Forfeited/Expired (in usd per share)	86.04
Balance, end of period (in usd per share)	69.95	$ 73.62
Vested and exercisable as of end of period (in usd per share)	$ 78.52
Weighted-Average Remaining Contractual Life (Years)
Balance, beginning of period	5 years	5 years 1 month 6 days
Balance, end of period	5 years	5 years 1 month 6 days
Vested and exercisable as of end of period	4 years 1 month 6 days
Aggregate Intrinsic Value
Balance, beginning of period	$ 306
Balance, end of period	43	$ 306
Vested and exercisable as of end of period	$ 31

Commitments and Contingencies (Details) - USD ($) $ in Thousands			3 Months Ended		6 Months Ended
	Sep. 12, 2024	Jul. 29, 2024	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Loss Contingencies [Line Items]
Purchase obligations			$ 59,600		$ 59,600
Expense related to cyber security incident			1,523	$ 0	10,952	$ 0
Cyber Security Incident
Loss Contingencies [Line Items]
Contemplated aggregate cash settlement	$ 30,000	$ 30,000
Privacy and monitoring service period		3 years
Expense related to cyber security incident			1,500		11,000
Litigation settlement expenses, net			33,100
Probable insurance recoveries			22,100		22,100
Loss contingency accrual			30,000		30,000
Insurance recoveries			$ 22,600		$ 22,600

Leases

6 Months Ended

Sep. 30, 2024

Leases [Abstract]

Leases

The Company has entered into operating leases for its corporate offices, lab facilities, and storage spaces, with remaining contractual periods ranging from 1.3 years to 6.8 years. For the Company’s facility in Sunnyvale, California (the “Sunnyvale facility”), there is an option to extend the lease for a period of seven years. The Company is not reasonably certain that it will exercise this option and therefore it is not included in its right-of-use (“ROU”) assets and lease liabilities as of September 30, 2024. The Company did not have any finance leases for the periods presented.

On September 16, 2024, the Company entered into an agreement with a third party to sublease 17,312 square feet of the Sunnyvale facility. The total rental commitment over the four-year term of the sublease is $3.2 million. The Company’s sublease agreement: (i) includes renewal and termination options; (ii) provides for customary escalations of lease payments in the normal course of business; (iii) grants the subtenant free rent for specific months during term; (iv) requires variable payments that are dependent on usage, output, or may vary for other reasons, such as insurance and tax payments; and (v) grants the subtenant title of furniture if it extends the lease. The sublease is classified as operating leases whereby sublease income is recognized on a straight-line basis over the sublease term that expires in 2028. Sublease income was $30 thousand for the three and six months ended September 30, 2024. There was no sublease income recognized during the three and six months ended September 30, 2023.

For the three months ended September 30, 2024 and 2023, the Company recorded operating lease costs of $3.3 million and $3.4 million, respectively, and variable operating lease costs of $1.4 million and $1.2 million, respectively. For the six months ended September 30, 2024 and 2023, the Company recorded operating lease costs of $6.7 million and $6.8 million, respectively, and variable operating lease costs of $2.9 million and $2.5 million, respectively.

As of September 30, 2024, the future minimum lease payments included in the measurement of the Company’s operating lease liabilities were as follows:


	September 30, 2024
	(in thousands)
Fiscal years ending March 31,
Remainder of 2025 (Remaining six months)	$	6,527
2026	15,946
2027	15,472
2028	11,666
2029	12,016
Thereafter	29,414
Total future operating lease payments	91,041
Less: imputed interest	(19,353)
Total operating lease liabilities	$	71,688

Summary of Significant Accounting Policies - Additional Information (Details) $ in Thousands					1 Months Ended	3 Months Ended			6 Months Ended
	Nov. 01, 2024 USD ($)	Oct. 16, 2024	Oct. 07, 2024	Aug. 26, 2024	May 31, 2023 USD ($)	Sep. 30, 2024 USD ($)	Jun. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Mar. 31, 2024 USD ($)
Concentration Risk [Line Items]
% of Revenue									100.00%	100.00%
Restricted cash						$ 10,500			$ 10,500		$ 8,400
Decrease in escrow deposit					$ 6,000		$ 6,200
Accumulated deficit						2,301,591			2,301,591		2,173,088
Cash and cash equivalents						$ 126,601		$ 256,386	$ 126,601	$ 256,386	$ 216,488
Percentage of total voting power of outstanding stock				67.00%
Subsequent Event
Concentration Risk [Line Items]
Reverse stock split		0.05	0.05
Increase in restricted cash	$ 3,500
Minimum
Concentration Risk [Line Items]
Reverse stock split				0.200
Maximum
Concentration Risk [Line Items]
Reverse stock split				0.0333
Microarrays \| Cost of Goods and Service, Product and Service Benchmark \| Supplier Concentration Risk
Concentration Risk [Line Items]
% of Revenue						100.00%		100.00%	100.00%	100.00%
K I T S \| Cost of Goods and Service, Product and Service Benchmark \| Supplier Concentration Risk
Concentration Risk [Line Items]
% of Revenue						100.00%		100.00%	100.00%	100.00%
Laboratory Services \| Cost of Goods and Service, Product and Service Benchmark \| Supplier Concentration Risk
Concentration Risk [Line Items]
% of Revenue						100.00%		100.00%

Stockholders' Equity - Additional Information (Details) $ / shares in Units, $ in Millions		3 Months Ended	6 Months Ended
	Feb. 06, 2023 USD ($)	Jun. 30, 2024	Sep. 30, 2024 Vote $ / shares shares	Mar. 31, 2024 shares
Class of Stock [Line Items]
Stock split description			Each share of Class B common stock is convertible into one share of Class A common stock any time at the option of the holder and is automatically converted into one share of Class A common stock upon transfer
Cowen and Company LLC
Class of Stock [Line Items]
Commission fees payable, percentage	3.00%
At-the Market Offering Program
Class of Stock [Line Items]
Sale of stock aggregate (up to) \| $	$ 150.0
VG Acquisition Sponsor LLC
Class of Stock [Line Items]
Lockup period for shares		7 years	7 years
Earn-out shares, percentage			50.00%
VG Acquisition Sponsor LLC \| Maximum
Class of Stock [Line Items]
Share price thresholds release from lock up (in usd per share) \| $ / shares			$ 300.00
Class A Common Stock
Class of Stock [Line Items]
Number of votes \| Vote			1
Class A Common Stock \| VG Acquisition Sponsor LLC
Class of Stock [Line Items]
Earnout shares (in shares) \| shares			190,707	190,707
Earn-out shares, percentage			50.00%
Trading days			20 days
Number of trading days after commencing			30 days
Class A Common Stock \| VG Acquisition Sponsor LLC \| Minimum
Class of Stock [Line Items]
Share price thresholds release from lock up (in usd per share) \| $ / shares			$ 250.00
Class B Common Stock
Class of Stock [Line Items]
Number of votes \| Vote			10

Variable Interest Entities	6 Months Ended
Variable Interest Entities	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Variable Interest Entities	Variable Interest Entities In providing telehealth services that include professional medical consultations, the Company maintains relationships with various affiliated professional medical corporations (“PMCs”). Additionally, with respect to its telehealth services involving the sale of prescription products, the Company maintains relationships with affiliated pharmacies (collectively, the “Affiliated Pharmacies”) to fill prescriptions that are ordered by the Company’s patients. On February 15, 2024, the Company acquired full ownership of the active Affiliated Pharmacies, and thereafter the Company ceased to treat the Affiliated Pharmacies as Variable Interest Entities (“VIEs”). The Company determined that the PMCs are, and prior to being acquired by the Company, the Affiliated Pharmacies were, VIEs, in each case due to the respective equity holders having nominal capital at risk and the Company having a variable interest in each of the PMCs and, prior to acquiring them, the Affiliated Pharmacies. Until February 15, 2024, the Company consolidated the PMCs and Affiliated Pharmacies under the VIE model since the Company had the power to direct activities that most significantly impact the VIEs’ economic performance and the right to receive benefits or the obligation to absorb losses that could potentially be significant to the VIEs. Under the VIE model, the Company presents the results of operations and the financial position of the VIEs as part of the condensed consolidated financial statements of the Company. There was no impact to the Company’s condensed consolidated financial statements as a result of the Affiliated Pharmacies being acquired by the Company. Furthermore, as a direct result of the financial support the Company provided to the VIEs (e.g., loans), the interests held by holders lacked economic substance and did not provide them with the ability to participate in the residual profits or losses generated by the VIEs. Therefore, all income and expenses recognized by the VIEs were allocated to the Company’s stockholders. The aggregate carrying value of total assets and total liabilities included on the condensed consolidated balance sheets for the VIEs after elimination of intercompany transactions were not material as of September 30, 2024 and March 31, 2024. Total revenue included in the condensed consolidated statements of operations and comprehensive loss for the VIEs after elimination of intercompany transactions was $0.9 million and $8.5 million for the three months ended September 30, 2024 and 2023, respectively, and $1.8 million and $17.5 million for the six months ended September 30, 2024 and 2023, respectively. The Company maintains the ability to control the VIEs, is entitled to substantially all of the economic benefits from the VIEs, and is obligated to absorb all expected losses of the VIEs.

Balance Sheet Components - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Mar. 31, 2024
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 110,012	$ 110,082
Less: accumulated depreciation and amortization	(85,198)	(81,731)
Property and equipment, net	24,814	28,351
Computer equipment and software
Property, Plant and Equipment [Line Items]
Property and equipment, gross	7,392	7,485
Laboratory equipment and software
Property, Plant and Equipment [Line Items]
Property and equipment, gross	51,363	51,635
Furniture and office equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	8,937	8,929
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	41,467	41,180
Capitalized asset retirement obligations
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 853	$ 853

Summary of Significant Accounting Policies (Policies)	6 Months Ended
Summary of Significant Accounting Policies (Policies)	Sep. 30, 2024
Accounting Policies [Abstract]
Basis of Presentation and Principle of Consolidation	Basis of Presentation and Principle of Consolidation The Company’s unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and include the accounts of the Company and its wholly owned subsidiaries, and variable interest entities in which it holds a controlling financial interest. All intercompany accounts and transactions have been eliminated in consolidation. For the three and six months ended September 30, 2024 and 2023, the Company’s operations were primarily in the United States. The Company had immaterial operations in the United Kingdom (“U.K.”) prior to the disposition of its U.K. subsidiary on August 1, 2023. There have been no material changes to the Company’s significant accounting policies during the six months ended September 30, 2024, as compared to the audited consolidated financial statements in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2024 filed with the SEC on May 30, 2024 (the “Fiscal 2024 Form 10-K”).
Change in Capital Structure	Change in Capital Structure As described more fully in Note 19, “Subsequent Events,” effective October 16, 2024, the Company effected a one-for-twenty reverse stock split of all of its issued and outstanding shares of Class A common stock and Class B common stock (the “Reverse Stock Split”). All share and per share amounts presented in the unaudited condensed consolidated financial statements and accompanying notes, including, but not limited to, shares issued and outstanding, dollar amounts of common stock, additional paid-in capital, earnings/(loss) per share, and options, have been retroactively adjusted for all periods presented in order to reflect this change in capital structure. There were no changes to the total numbers of authorized shares of Class A common stock and Class B common stock or their respective par values per share as a result of this change.
Unaudited Interim Condensed Consolidated Financial Information	Unaudited Interim Condensed Consolidated Financial Information The accompanying interim condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements (the “condensed consolidated financial statements”) have been prepared in accordance with GAAP applicable to interim financial statements. These financial statements are presented in accordance with the rules and regulations of the SEC and do not include all disclosures normally required in annual consolidated financial statements prepared in accordance with GAAP. As such, the information included herein should be read in conjunction with the consolidated financial statements and accompanying notes as of and for the fiscal year ended March 31, 2024 (the “audited consolidated financial statements”) that were included in the Fiscal 2024 Form 10-K. In management’s opinion, the unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements, which include only normal recurring adjustments, necessary for a fair statement of the Company’s financial position as of September 30, 2024 and its condensed consolidated results of operations and cash flows for the six months ended September 30, 2024 and 2023. The results of operations for the three and six months ended September 30, 2024 are not necessarily indicative of the results expected for the year ending March 31, 2025 or any other future interim or annual periods, due to among other factors, the seasonal nature of the business.
Fiscal Year	Fiscal Year The Company’s fiscal year ends on March 31. References to fiscal 2025 refer to the fiscal year ending March 31, 2025 and references to fiscal 2024 and fiscal 2023 refer to the fiscal years ended March 31, 2024 and March 31, 2023, respectively.
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities and the related disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period and the accompanying notes. Significant items subject to such estimates and assumptions include, but are not limited to the determination of standalone selling price for various performance obligations; the estimated expected benefit period for the rate and recognition pattern of breakage revenue for purchases where a saliva collection kit (“kit”) is never returned for processing; the capitalization and estimated useful life of internal use software; the useful life of long-lived assets; fair value of intangible assets acquired in business combinations; the incremental borrowing rate for operating leases; stock-based compensation including the determination of the fair value of stock options and annual incentive bonuses payable in the form of restricted stock units (“RSUs”); the assumptions used in going concern assessments; and the valuation of deferred tax assets and uncertain tax positions. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that it believes are reasonable under the circumstances, including assumptions as to future events. Actual results could differ from these estimates, and such differences could be material to the condensed consolidated financial statements. The Company is not aware of any specific event or circumstance that would require revisions to estimates, updates to judgments, or adjustments to the carrying value of assets or liabilities. These estimates may change, as new events occur and/or additional information is obtained, and will be recognized in the condensed consolidated financial statements as soon as they become known.
Concentration of Supplier Risk	Concentration of Supplier Risk Certain of the raw materials, components, and equipment associated with the deoxyribonucleic acid (“DNA”) microarrays and kits used by the Company in the delivery of its services are available only from third-party suppliers. The Company also relies on a third-party laboratory service for the processing of its customer samples. Shortages and slowdowns could occur in these essential materials, components, equipment, and laboratory services due to an interruption of supply or increased demand in the industry. If the Company were unable to procure certain materials, components, equipment, or laboratory services at acceptable prices, it would be required to reduce its laboratory operations, which could have a material adverse effect on its results of operations. A single supplier accounted for 100% of the Company’s total purchases of microarrays, and a separate single supplier accounted for 100% of the Company’s total purchases of kits for the three and six months ended September 30, 2024 and 2023. One laboratory service provider accounted for 100% of the Company’s processing of customer samples for the three and six months ended September 30, 2024 and 2023.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk include cash, cash equivalents, and accounts receivable. The Company maintains a majority of its cash and cash equivalents with a single high-quality financial institution, the composition and maturities of which are regularly monitored by the Company. The Company’s revenue and accounts receivable are derived primarily from the United States. See Note 3, “Revenue,” for additional information regarding geographical disaggregation of revenue. The Company grants credit to its customers in the normal course of business, performs credit evaluations of its significant customers on an as-needed basis, and does not require collateral. Concentrations of credit risk are limited as the Company’s trade receivables are primarily related to third parties, which collect its credit card receivables, and large multinational corporations. The Company regularly monitors the aging of accounts receivable balances.
Cash, Cash Equivalents and Restricted Cash	Cash, Cash Equivalents and Restricted Cash Cash consists of bank deposits held at financial institutions. Cash in U.S. banks is insured to the extent defined by the Federal Deposit Insurance Corporation. Cash equivalents consist primarily of short-term money market funds. The Company maintains certain cash amounts restricted as to its withdrawal or use, which are related to letters of credit in connection with the Company's Sunnyvale operating lease agreement and the Company’s credit card processor, as well as collateral held against the Company’s corporate credit cards. The Company held total restricted cash of $10.5 million and $8.4 million as of September 30, 2024 and March 31, 2024, respectively. The increase in restricted cash related to a new letter of credit entered into by the Company in April 2024 as collateral related to the Company’s credit card processor. On November 1, 2024, there was a $3.5 million increase in the restricted cash balances related to an amended letter of credit entered into by the Company as collateral related to the Company’s credit card processor.
Cash, Cash Equivalents and Restricted Cash	Cash, Cash Equivalents and Restricted Cash Cash consists of bank deposits held at financial institutions. Cash in U.S. banks is insured to the extent defined by the Federal Deposit Insurance Corporation. Cash equivalents consist primarily of short-term money market funds. The Company maintains certain cash amounts restricted as to its withdrawal or use, which are related to letters of credit in connection with the Company's Sunnyvale operating lease agreement and the Company’s credit card processor, as well as collateral held against the Company’s corporate credit cards. The Company held total restricted cash of $10.5 million and $8.4 million as of September 30, 2024 and March 31, 2024, respectively. The increase in restricted cash related to a new letter of credit entered into by the Company in April 2024 as collateral related to the Company’s credit card processor. On November 1, 2024, there was a $3.5 million increase in the restricted cash balances related to an amended letter of credit entered into by the Company as collateral related to the Company’s credit card processor.
Escrow Related to Acquisition	Escrow Related to Acquisition On November 1, 2021, the Company completed its acquisition of Lemonaid Health, and upon the acquisition closing date, funds were placed in escrow to cover a potential purchase price adjustment and to secure the indemnification obligations of the former equity holders of Lemonaid Health. In May 2023, $6.0 million of the escrow amount was released. The remaining escrow amount of $6.2 million was released during the first quarter of fiscal 2025. Accordingly, the entire escrow amount has been released.
Liquidity and Going Concern	Liquidity and Going Concern Going Concern The unaudited interim condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates continuity of operations, realization of assets, and the satisfaction of liabilities in the normal course of business. In accordance with Subtopic 205-40, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that the unaudited interim condensed consolidated financial statements included in this report are issued. The Company has incurred significant operating losses as reflected in its accumulated deficit and negative cash flows from operations. As of September 30, 2024, the Company had an accumulated deficit of $2.3 billion, and cash and cash equivalents of $126.6 million. The Company will need additional liquidity to fund its necessary expenditures and financial commitments for 12 months after the date that the unaudited interim condensed consolidated financial statements included in this report are issued. The Company has determined that, as of the filing date of this report, there is substantial doubt about the Company’s ability to continue as a going concern. To improve its financial condition and liquidity position, the Company is working to execute its business plan, manage ongoing operational expenses, and implement cost-cutting measures, as well as raising additional capital. See Note 19, “Subsequent Events,” for additional details. The Company’s ability to continue as a going concern, however, is contingent upon the Company’s ability to successfully implement its operational and financial plans, and if the Company fails to do so and/or is unable to raise sufficient capital or consummate a strategic transaction, it could be forced to modify or cease operations. While the Company believes in the viability of its strategy, there are numerous risks and uncertainties that may prevent, and there can be no assurances regarding, the successful implementation of the Company’s operational and financial plans and/or the consummation of any transactions. See Note 1, “Organization and Description of Business” for additional details. The unaudited interim condensed consolidated financial statements do not reflect any adjustments pertaining to the recoverability and classification of assets or the amount and classification of liabilities or any other adjustments that would be necessary if the Company were unable to continue as a going concern. Nasdaq Deficiency Minimum Bid Price On November 10, 2023, the Company received a deficiency letter (the “First Nasdaq Letter”) from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that it was not in compliance with Nasdaq Listing Rule 5450(a)(1), which requires the Company to maintain a minimum bid price of at least $1.00 per share for continued listing on The Nasdaq Global Select Market (the “Minimum Bid Requirement”). The Company’s failure to comply with the Minimum Bid Requirement was based on its Class A common stock per share price being below the $1.00 threshold for a period of 30 consecutive trading days. Pursuant to the First Nasdaq Letter, the Company had an initial 180 calendar days from the date of the First Nasdaq Letter to regain compliance. The Company did not regain compliance during the initial compliance period. On May 9, 2024, the Company received a notification letter from the Staff notifying the Company that it had been granted an additional 180 days, or until November 4, 2024, to regain compliance with the Minimum Bid Requirement, based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on The Nasdaq Capital Market with the exception of the bid price requirement, and the Company’s written notice of its intention to cure the deficiency during the second compliance period. In order to be eligible to receive the second compliance period, the Company applied to have its Class A common stock transferred from the Nasdaq Global Select Market to the Nasdaq Capital Market. In connection with the foregoing, on July 16, 2024, the Company filed a Definitive Proxy Statement on Schedule 14A with the SEC in connection with the Company’s 2024 Annual Meeting of Stockholders, which was held on August 26, 2024 (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders, by an affirmative vote of the holders of at least two-thirds (67%) of the voting power of the outstanding shares of the Company’s Class A common stock and Class B common stock voting together as a single class, approved a proposal authorizing the Company’s Board of Directors, in its discretion, to effect a reverse stock split of the Company’s outstanding shares of Class A common stock and Class B common stock, respectively, by a ratio of not less than one-for-five and not more than one-for-thirty, with the exact ratio to be set within this range by the Company’s Board of Directors in its sole discretion. On October 7, 2024, the Company’s Board of Directors approved the Reverse Stock Split at a ratio of one-for-twenty. The Reverse Stock Split became effective as of 12:01 a.m. Eastern Time on October 16, 2024, and on October 30, 2024, the Company regained compliance with the Minimum Bid Requirement. See Note 19, “Subsequent Events,” for additional details. Nasdaq Deficiency Independent Directors On September 18, 2024, the Company received a deficiency letter from the Staff, notifying the Company that the Company was not in compliance with Nasdaq Listing Rule 5605 (the “Second Nasdaq Letter”). Specifically, as a result of the Resignations, the Company was no longer in compliance with the following (collectively, the “Corporate Governance Requirements”): •Nasdaq Listing Rule 5605(b), which requires, among other things, that a majority of the Company’s Board of Directors be comprised of Independent Directors (as defined in Nasdaq Listing Rule 5605(a)(2)); •Nasdaq Listing Rule 5605(c), which requires, among other things, that the Company have an Audit Committee that has at least three members, each of whom must (i) be an Independent Director, (ii) meet the criteria for independence set forth in Rule 10A-3(b)(1) under the Securities Exchange Act of 1934, as amended, (iii) not have participated in the preparation of the financial statements of the Company or any current subsidiary of the Company at any time during the past three years, and (iv) be able to read and understand fundamental financial statements; •Nasdaq Listing Rule 5605(d), which requires, among other things, that the Company have a Compensation Committee that has at least two members, each of whom must be an Independent Director; and •Nasdaq Listing Rule 5605(e), which requires, among other things, that the Company have Independent Director oversight of director nominations. Pursuant to the Second Nasdaq Letter, the Company had until October 3, 2024 to submit a plan to regain compliance with the Corporate Governance Requirements (the “Plan”) for the Staff’s review. The Company submitted the Plan to the Staff on September 26, 2024, and on October 30, 2024, the Company regained compliance with the Corporate Governance Requirements. See Note 19, “Subsequent Events” for additional details.
Recently Issued Accounting Pronouncements Not Yet Effective	Recently Issued Accounting Pronouncements Not Yet Effective In November 2023, the Financial Accounting Standard Board (“FASB”) issued Accounting Standard Updated (“ASU”) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires disclosure of incremental segment information on an annual and interim basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and requires retrospective application to all prior periods presented in the financial statements. Early adoption is permitted. The Company is currently evaluating the impacts of the new standard. In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which expands disclosures in an entity’s income tax rate reconciliation table and income taxes paid information. This ASU is effective for fiscal years beginning after December 15, 2024 and may be adopted on a prospective or retrospective basis. Early adoption is permitted. The Company is currently evaluating the impacts and method of adoption. In November 2024, the FASB issued ASU No. 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures, which requires more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation, amortization, and depletion) included in certain expense captions presented on the face of the income statement. This ASU is effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact of this new standard.

Subsequent Events	6 Months Ended
Subsequent Events	Sep. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Capital Structure - Reverse Stock Split As previously disclosed, at the Annual Meeting, the Company’s stockholders, by an affirmative vote of the holders of at least two-thirds (67%) of the voting power of the outstanding shares of the Company’s Class A common stock and Class B common stock, voting together as a single class, approved a proposal authorizing the Company’s Board of Directors, in its discretion, to effect a reverse stock split of the Company’s outstanding shares of Class A common stock and Class B common stock, respectively, by a ratio of not less than one-for-five and not more than one-for-thirty, with the exact ratio to be set within this range by the Company’s Board of Directors in its sole discretion. On October 7, 2024, the Board approved the Reverse Stock Split at a ratio of one-for-twenty, to be effective at 12:01 a.m. Eastern Time on October 16, 2024. On October 11, 2024, the Company filed the Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware to effect the Reverse Stock Split, which became effective as of 12:01 a.m., Eastern Time on October 16, 2024. As a result of the Reverse Stock Split, every 20 shares of the Company’s Class A common stock and Class B common stock were automatically combined into one issued and outstanding share of the Company’s respective Class A common stock and Class B common stock, without any change in their respective par values per share. The Company did not issue fractional shares in connection with the Reverse Stock Split. Instead, stockholders who otherwise would have been entitled to receive fractional shares because they held a number of shares not evenly divisible by the Reverse Stock Split ratio were automatically entitled to receive an additional fraction of a share of Class A common stock or Class B common stock, as applicable, to round up to the next whole share. Commencing on October 16, 2024, trading of the Company’s Class A common stock continued on The Nasdaq Capital Market on a Reverse Stock Split-adjusted basis. The Company’s trading symbol remains “ME.” The impact of the Reverse Stock Split was applied retroactively for all periods presented in accordance with applicable guidance. There was no change to the total number of authorized shares of Class A common stock of 1,140,000,000 and the total number of authorized shares of Class B common stock of 350,000,000. Nasdaq Minimum Bid Requirement On October 30, 2024, the Company received written notice (the “Compliance Notice”) from the Staff informing the Company that it has regained compliance with the Minimum Bid Requirement. The Staff notified the Company in the Compliance Notice that, from October 16, 2024 to October 29, 2024, the closing bid price of the Company’s Class A common stock had been $1.00 per share or greater and, accordingly, the Company had regained compliance with the Minimum Bid Requirement and that the matter was now closed. Appointment of Independent Directors and Nasdaq Listing Rule 5605 On October 29, 2024, the Company announced the appointment of three independent directors to the Company’s Board of Directors, each of whom were appointed to the Audit Committee and Compensation Committee (the “Appointments”). On October 30, 2024, the Company received a letter from the Staff informing the Company that, as a result of the Appointments, the Company has regained compliance with the Corporate Governance Requirements. Costs Associated with Exit or Disposal Activities On November 8, 2024, the Company’s Board of Directors approved a reduction in force related to both its Consumer and Therapeutics segments (the “November Reduction in Force.”) The November Reduction in Force also includes the closure of substantially all operations in the Company’s Therapeutics operating segment (together with the November Reduction in Force, the “Reduction Plan”). The Reduction Plan is intended to restructure and strategically align the Company’s workforce and organization with the Company’s current strategy and to reduce the Company’s operating costs. The Company expects to complete the Reduction Plan substantially during the third quarter of its fiscal 2025, with certain affected employees retained through a transition period expected to end no later than the end of fiscal 2025. The Company expects to recognize restructuring charges in connection with the November Reduction in Force with respect to severance payments, benefits continuation, and stock compensation charges associated with the modification of certain stock options and restricted stock units (“equity compensation charges”). All such charges are expected to total approximately $11.7 million, of this amount, severance payments and benefit continuation charges are estimated to be approximately $9.3 million and are expected to be recognized primarily during the third quarter of fiscal 2025, with the majority of such charges anticipated to be paid in cash during the same fiscal quarter. Equity compensation charges are expected to be approximately $2.4 million and are expected to be recognized primarily in the third quarter of fiscal 2025, and will not result in any cash expenditures.

Organization and Description of Business	6 Months Ended
Organization and Description of Business	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	Organization and Description of Business 23andMe Holding Co. (the “Company” or “23andMe”) is dedicated to helping people access, understand, and benefit from the human genome. The Company is building the leading direct-to-consumer precision medicine platform that powers its genetics-driven therapeutics and research business. The Company is dedicated to empowering customers to optimize their health by providing consumers direct access to their genetic information, personalized reports, actionable insights, and digital access to affordable healthcare professionals through the Company’s telehealth platform, Lemonaid Health, Inc. (“Lemonaid Health”). The Company pioneered direct-to-consumer genetic testing, giving consumers unique, personalized information about their genetic health risks, ancestry, and traits. It was the first company to obtain Food and Drug Administration (“FDA”) authorization for a direct-to-consumer genetic test, and it is the only company to have FDA authorization, clearance, or an exemption from premarket notification for all of the carrier status, genetic health risk, cancer predisposition, and pharmacogenetics reports that the Company offers to customers. Through the Lemonaid Health telehealth platform, the Company connects patients to licensed healthcare professionals to provide affordable and direct online access to medical care, from consultation through treatment, for a number of common conditions, using evidence-based guidelines and up-to-date clinical protocols. When medications are prescribed by Lemonaid Health’s affiliated healthcare professionals, patients can use Lemonaid Health’s online pharmacy for fulfillment. Patients also can access telehealth consultations for certain 23andMe genetic reports through Lemonaid Health. As previously disclosed, the Company formed a special committee composed of independent members of the Board of Directors (the “Special Committee”) on March 28, 2024. The role of the Special Committee was to review strategic alternatives that may be available to the Company to maximize stockholder value. On April 17, 2024, Anne Wojcicki, Chief Executive Officer (“CEO”), Co-Founder, and Chair of the Board of Directors of the Company disclosed that she is considering making a proposal to acquire all of the outstanding shares of the Company that she does not currently own. Ms. Wojcicki also indicated that she wishes to maintain control of the Company and, therefore, will not be willing to support any alternative transaction. As previously disclosed, on July 29, 2024, the Special Committee received a preliminary non-binding indication of interest from Ms. Wojcicki to acquire all of the outstanding shares of the Company not owned by her or her affiliates or any other stockholder that she invites to roll over their shares, for cash consideration of $0.40 per share (on a pre-Reverse Stock Split basis) (the “Preliminary Proposal”), as set forth in Amendment No. 2 to Schedule 13D filed by ABeeC 2.0 LLC (Ms. Wojcicki’s affiliated entity) (“ABeeC”) with the Securities and Exchange Commission (the “SEC”) on July 31, 2024. On August 2, 2024, the Company issued a press release announcing the Special Committee’s response to the Preliminary Proposal, including certain requirements for any revised proposal from Ms. Wojcicki. As disclosed in Amendment No. 3 to Schedule 13D filed by ABeeC with the SEC on September 11, 2024, in response to requests from the Special Committee, on September 9, 2024, Ms. Wojcicki notified the members of the Special Committee that Ms. Wojcicki would be open to considering third-party takeover proposals for the Company. On September 17, 2024, the Company issued a press release regarding the resignations of seven non-employee directors (collectively, the “Resigning Directors”) from the Company’s Board of Directors (the “Resignations”). As set forth in the Resigning Directors’ resignation letter dated September 17, 2024, the Resigning Directors stated that such Resigning Directors differed from Ms. Wojcicki on the strategic direction for the Company, and that, as a result of such difference and Ms. Wojcicki’s concentrated voting power, the Resigning Directors believed that it was in the best interest of the Company’s stockholders to resign from the Board of Directors. In Amendment No. 4 to Schedule 13D filed by ABeeC with the SEC on September 18, 2024, Ms. Wojcicki announced that the Company will immediately begin identifying independent directors to join the Company’s Board of Directors. In Amendment No. 5 to Schedule 13D filed by ABeeC with the SEC on September 30, 2024, Ms. Wojcicki disclosed that she was no longer open to considering any third-party proposals to buy the Company and that she remains committed to completing a take-private acquisition of the Company. In connection with the Company’s announcement of the appointment of three independent directors to the Company’s Board of Directors, ABeeC filed Amendment No. 6 to Schedule 13D with the SEC on October 29, 2024. Each of the newly-appointed independent directors was subsequently appointed to the Special Committee on November 2, 2024, See Note 19, “Subsequent Events,” for additional details. The Company has evaluated how it is organized and managed and has identified two reporting segments: (1) Consumer and Research Services, and (2) Therapeutics. The Company is headquartered in Sunnyvale, California and is incorporated in the State of Delaware.

Revenue - Schedule of Revenue by Region Based on the Shipping Address of Customers (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Disaggregation of Revenue [Line Items]
Amount	$ 44,071	$ 49,999	$ 84,485	$ 110,863
% of Revenue			100.00%	100.00%
Revenue \| Geographic Concentration Risk
Disaggregation of Revenue [Line Items]
% of Revenue	100.00%	100.00%	100.00%	100.00%
United States
Disaggregation of Revenue [Line Items]
Amount	$ 38,671	$ 42,185	$ 73,956	$ 85,511
United States \| Revenue \| Geographic Concentration Risk
Disaggregation of Revenue [Line Items]
% of Revenue	88.00%	84.00%	88.00%	77.00%
United Kingdom
Disaggregation of Revenue [Line Items]
Amount	$ 1,968	$ 4,163	$ 4,092	$ 18,518
United Kingdom \| Revenue \| Geographic Concentration Risk
Disaggregation of Revenue [Line Items]
% of Revenue	4.00%	8.00%	5.00%	17.00%
Canada
Disaggregation of Revenue [Line Items]
Amount	$ 2,402	$ 2,558	$ 4,417	$ 4,728
Canada \| Revenue \| Geographic Concentration Risk
Disaggregation of Revenue [Line Items]
% of Revenue	5.00%	5.00%	5.00%	4.00%
Other regions
Disaggregation of Revenue [Line Items]
Amount	$ 1,030	$ 1,093	$ 2,020	$ 2,106
Other regions \| Revenue \| Geographic Concentration Risk
Disaggregation of Revenue [Line Items]
% of Revenue	3.00%	3.00%	2.00%	2.00%

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

Restructuring - Schedule of Restructuring and Related Costs (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Restructuring Reserve [Roll Forward]
Accrued restructuring costs included in accrued expenses and other current liabilities as of March 31, 2024			$ 22
Restructuring charges incurred during the period	$ 2,242	$ 2,654	2,242	$ 6,871
Amounts paid during the period			(2,017)
Accrued restructuring costs included in accrued expenses and other current liabilities as of September 30, 2024	$ 247		$ 247

Restructuring (Tables)

6 Months Ended

Sep. 30, 2024

Restructuring and Related Activities [Abstract]

Schedule of Restructuring and Related Costs

The following table shows the total amount incurred and accrued related to one-time employee termination benefits:


	One-Time Employee Termination Benefits
	(in thousands)
Accrued restructuring costs included in accrued expenses and other current liabilities as of March 31, 2024	$	22
Restructuring charges incurred during the period	2,242
Amounts paid during the period	(2,017)
Accrued restructuring costs included in accrued expenses and other current liabilities as of September 30, 2024	$	247

Summary of Significant Accounting Policies - Schedule of Significant Customer Information (Details)	3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Mar. 31, 2024
Concentration Risk [Line Items]
% of Revenue			100.00%	100.00%
Customer Concentration Risk \| Customer C \| Accounts Receivable
Concentration Risk [Line Items]
% of Revenue			10.00%		59.00%
Customer Concentration Risk \| Customer C \| Revenue
Concentration Risk [Line Items]
% of Revenue	26.00%	26.00%	23.00%	21.00%
Customer Concentration Risk \| Customer F \| Accounts Receivable
Concentration Risk [Line Items]
% of Revenue			55.00%		0.00%
Customer Concentration Risk \| Customer I \| Accounts Receivable
Concentration Risk [Line Items]
% of Revenue			0.00%		30.00%
Customer Concentration Risk \| Customer J \| Accounts Receivable
Concentration Risk [Line Items]
% of Revenue			14.00%
Customer Concentration Risk \| Customer K \| Accounts Receivable
Concentration Risk [Line Items]
% of Revenue			17.00%
Customer Concentration Risk \| Customer B \| Revenue
Concentration Risk [Line Items]
% of Revenue				11.00%

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Sep. 30, 2024	Jun. 30, 2024	Sep. 30, 2023	Jun. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net loss	$ (59,103)	$ (69,400)	$ (75,270)	$ (104,624)	$ (128,503)	$ (179,894)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Collaborations	6 Months Ended
Collaborations	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaborations	Collaborations GlaxoSmithKline Agreement and Subsequent Amendments In July 2018, the Company and an affiliate of GlaxoSmithKline (“GSK”) entered into a four-year exclusive drug discovery and development collaboration agreement, amended in 2019 and 2021, respectively (as amended, the “original GSK Agreement”), for collaboration on identification and development of therapeutic agents with a unilateral option for GSK to extend the term for an additional year. In January 2022, GSK elected to exercise the option to extend the exclusive target discovery term for an additional year to July 23, 2023, after which it expired under the original GSK Agreement. The Company has concluded that GSK is considered a customer. Therefore, the Company applied the guidance in ASC 606 to account for and present consideration received from GSK related to research services provided by the Company. The Company’s activities under the original GSK Agreement, which included reporting, drug target discovery, and joint steering committee participation, represented one combined performance obligation to deliver research services. The Company recognized research services revenue related to the original GSK Agreement as the respective performance obligations were satisfied using an input method to measure progress. In addition, the original GSK Agreement, provided GSK the right to include certain identified pre-existing Company programs in the collaboration at GSK’s election, each of which was considered distinct from the research services. Prior to the expiration of the original GSK Agreement, drug targets were identified for inclusion in the collaboration during the performance of research services. Cost sharing related to the performance of research services was recorded when incurred within cost of revenue in the Consumer and Research Services segment. For the drug targets that had been identified for inclusion in the original collaboration, the Company and GSK continue to equally share in the costs of further research, development, and commercialization of identified targets under the original GSK Agreement, subject to certain rights of either party to opt-out of funding at certain predetermined development milestones. These cost-sharing charges for the program costs incurred subsequent to the identification of drug targets have been included in research and development expense on the condensed consolidated statements of operations and comprehensive loss during the period incurred. The Company may also share in the net profits or losses of products that are commercialized pursuant to the collaboration or receive royalties on products which are successfully commercialized. In October 2023, the Company entered into an amendment to the original GSK Agreement (the “2023 GSK Amendment”) to provide GSK with a non-exclusive license to certain new, de-identified, aggregated data included in the Company’s database (the “New Data”), as well as access to certain Company research services with respect to such New Data in return for a $20.0 million data access fee, which the Company received during fiscal 2024. The license to the New Data will expire one year from the date GSK provides the Company with a notice that GSK was ready to use the New Data (the “Data Use Notice”); in September 2024, the Company and GSK agreed to extend the deadline for the Data Use Notice from September 30, 2024 to October 28, 2024. Revenue attributable to the New Data license was accounted for upon the satisfaction of performance obligations and was recognized upon the Company’s receipt of the Data Use Notice from GSK, which occurred on October 28, 2024. Revenue attributable to research services will be recognized as the performance obligation is satisfied using an input method to measure progress. The Company believes that actual hours incurred relative to contractually agreed upon hours is the most accurate measurement of progress for the input method. As of September 30, 2024, deferred revenue associated with the New Data access was $20.0 million. The license to the New Data will expire on October 28, 2025. Pursuant to the 2023 GSK Amendment, the Company opted-out of cost-sharing and other research and development obligations with respect to three programs initiated by GSK and the Company under the original GSK Agreement. The Company will retain rights to receive low to mid-single digit royalties on net sales of products developed in these three programs. The Company recognized research services revenue related to the original GSK Agreement of nil and $1.1 million during the three months ended September 30, 2024 and 2023, respectively, and nil and $11.8 million during the six months ended September 30, 2024 and 2023, respectively. The Company recognized research services revenue related to the 2023 GSK Amendment of $17 thousand during the three and six months ended September 30, 2024. The Company did not recognize research services revenue related to the 2023 GSK Amendment during the three and six months ended September 30, 2023. As of September 30, 2024 and March 31, 2024, the Company had deferred revenue of $20.0 million related to the 2023 GSK Amendment. Cost-sharing amounts incurred prior to the identification of targets included in cost of revenue were nil during the three and six months ended September 30, 2024, and immaterial for the three and six months ended September 30, 2023. Cost-sharing amounts incurred subsequent to the identification of targets, included in research and development expenses, were $(0.4) million and $0.2 million during the three and six months ended September 30, 2024, respectively, and $4.9 million and $8.2 million during the three and six months ended September 30, 2023, respectively. As of September 30, 2024 and March 31, 2024, the Company had $1.9 million and $10.6 million, respectively, related to balances of amounts payable to GSK for reimbursement of shared costs included within accounts payable and accrued expenses and other current liabilities on the condensed consolidated balance sheets. GSK’s affiliate, Glaxo Group Limited, is considered as a related party to the Company. See Note 18 “Related Party Transactions.”

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Sep. 30, 2024

Accounting Policies [Abstract]

Schedule of Significant Customer Information

Significant customer information is as follows:


	September 30, 2024		March 31, 2024
Percentage of accounts receivable:
Customer C(1)	10	%	59	%
Customer F	55	%	—	%
Customer I	—	%	30	%
Customer J	14	%	*
Customer K	17	%	*

•less than 10%

(1)Customer C is a reseller.


	Three Months Ended September 30,				Six Months Ended September 30,
	2024		2023		2024		2023
Percentage of revenue:
Customer C(1)	26	%	26	%	23	%	21	%
Customer B	*		*		*		11	%

•less than 10%

(1)Customer C is a reseller.

Segment Information - Schedule of Revenue and Adjusted EBITDA by Segment (Details) - USD ($)	3 Months Ended				6 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Sep. 30, 2023	Jun. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Segment Revenue
Total revenue	$ 44,071,000		$ 49,999,000		$ 84,485,000	$ 110,863,000
Segment Adjusted EBITDA:
Total Adjusted EBITDA	(33,412,000)		(45,053,000)		(68,574,000)	(94,853,000)
Net loss	(59,103,000)	$ (69,400,000)	(75,270,000)	$ (104,624,000)	(128,503,000)	(179,894,000)
Adjustments:
Interest income, net	(2,009,000)		(3,752,000)		(4,583,000)	(8,059,000)
Other (income) expense, net	(15,000)		(145,000)		4,000	(477,000)
Provision for (benefit from) income taxes	(41,000)		36,000		(41,000)	36,000
Depreciation and amortization	4,972,000		4,474,000		8,983,000	8,951,000
Amortization of acquired intangible assets	1,775,000		3,638,000		3,551,000	7,277,000
Stock-based compensation expense	19,486,000		23,741,000		41,063,000	74,840,000
Loss on disposition of Lemonaid Health Limited and transaction-related costs	0		2,127,000		0	2,375,000
Litigation settlement cost	0		98,000		0	98,000
Cyber security incident expenses, net of probable insurance recoveries	1,523,000		0		10,952,000	0
Total Adjusted EBITDA	(33,412,000)		(45,053,000)		(68,574,000)	(94,853,000)
Corporate, Non-Segment
Segment Adjusted EBITDA:
Total Adjusted EBITDA	(12,804,000)		(12,156,000)		(26,708,000)	(25,215,000)
Consumer and Research Services
Segment Revenue
Total revenue	44,071,000		49,999,000		84,485,000	110,863,000
Consumer and Research Services \| Operating Segments
Segment Adjusted EBITDA:
Total Adjusted EBITDA	(8,633,000)		(6,673,000)		(17,474,000)	(12,275,000)
Therapeutics
Segment Revenue
Total revenue	0		0		0	0
Therapeutics \| Operating Segments
Segment Adjusted EBITDA:
Total Adjusted EBITDA	$ (11,975,000)		$ (26,224,000)		$ (24,392,000)	$ (57,363,000)

Balance Sheet Components - Schedule of Accrued Expense and Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Mar. 31, 2024
Balance Sheet Related Disclosures [Abstract]
Accrued payables	$ 8,660	$ 9,697
Accrued settlement and legal expenses	34,525	3,260
Accrued compensation and benefits	3,235	4,266
Accrued vacation	6,643	7,221
Accrued bonus	7,696	7,420
Accrued clinical expenses	5,467	9,291
Accrued taxes and other	1,102	1,108
Total accrued expenses and other current liabilities	$ 67,328	$ 42,263

Net Loss Per Share Attributable to Common Stockholders

6 Months Ended

Sep. 30, 2024

Earnings Per Share [Abstract]

Net Loss Per Share Attributable to Common Stockholders

The net loss attributable to common stockholders is allocated on a proportionate basis, and the resulting net loss per share is identical for Class A common stock and Class B common stock under the two-class method.

The Company’s stock options, RSUs, restricted stock awards subject to vesting, estimated RSUs to be issued under the AIP, and estimated shares to be issued under the ESPP are considered to be potential common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders as their effect is anti-dilutive.

Net loss attributable to common stockholders was equivalent to net loss for all periods presented.

The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the periods presented:


	Three Months Ended September 30,								Six Months Ended September 30,
	2024				2023				2024				2023
	Class A		Class B		Class A		Class B		Class A		Class B		Class A		Class B
	(in thousands, except share and per share data)
Numerator:
Net loss attributable to common stockholders	$	(39,822)	$	(19,281)	$	(48,699)	$	(26,571)	$	(85,949)	$	(42,554)	$	(115,546)	$	(64,348)
Denominator:
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted	17,194,568		8,325,090		15,361,280		8,381,634		16,822,770		8,329,218		15,048,689		8,380,911
Net loss per share attributable to common stockholders:
Net loss per share attributable to common stockholders, basic and diluted	$	(2.32)	$	(2.32)	$	(3.17)	$	(3.17)	$	(5.11)	$	(5.11)	$	(7.68)	$	(7.68)

The potential shares of Class A common stock outstanding that were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti-dilutive were as follows:


	Three and Six Months Ended September 30,
	2024	2023
Outstanding stock options	3,134,850	3,781,897
Unvested restricted stock units	3,401,997	2,036,251
Shares subject to vesting	—	15,066
ESPP	325,939	283,111
Total	6,862,786	6,116,325

There were no potential shares of Class B common stock that were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented.

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2024	Mar. 31, 2024
Accounts payable, related party	$ 6,486	$ 11,571
Accrued expenses and other current liabilities, related party	67,328	42,263
Deferred revenue, current, related party	69,751	64,827
Deferred revenue, noncurrent related party	$ 0	$ 10,000
Preferred stock, par value (in usd per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in usd per share)	$ 0.0001	$ 0.0001
Class A Common Stock
Common stock, shares authorized (in shares)	1,140,000,000	1,140,000,000
Common stock, shares issued (in shares)	17,514,204	16,169,741
Common stock, shares outstanding (in shares)	17,514,204	16,169,741
Class B Common Stock
Common stock, shares authorized (in shares)	350,000,000	350,000,000
Common stock, shares issued (in shares)	8,322,160	8,336,229
Common stock, shares outstanding (in shares)	8,322,160	8,336,229
Related Party
Accounts payable, related party	$ 0	$ 3,809
Accrued expenses and other current liabilities, related party	1,930	6,752
Deferred revenue, current, related party	21,659	10,999
Deferred revenue, noncurrent related party	$ 0	$ 10,000

Fair Value Measurements (Details) - USD ($)	6 Months Ended	12 Months Ended
Fair Value Measurements (Details) - USD ($)	Sep. 30, 2024	Mar. 31, 2024
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value transfers between levels	$ 0	$ 0
Money Market Funds \| Fair Value, Inputs, Level 1
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	$ 121,000,000.0	$ 211,000,000.0

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

Sep. 30, 2024

Sep. 30, 2023

Sep. 30, 2024

Sep. 30, 2023

Revenue:

Total revenue

$ 44,071

$ 49,999

$ 84,485

$ 110,863

Cost of revenue:

Total cost of revenue

21,664

28,270

41,564

58,453

Gross profit

22,407

21,729

42,921

52,410

Operating expenses:

Research and development (includes related party expenses of $(386) and $4,907 for the three months ended September 30, 2024 and 2023, respectively, and $185 and $8,208 for the six months ended September 30, 2024 and 2023, respectively)

41,041

54,588

85,678

116,917

Sales and marketing

16,874

18,328

32,346

40,986

General and administrative

23,418

25,290

55,778

76,030

Restructuring and other charges

2,242

2,654

2,242

6,871

Total operating expenses

83,575

100,860

176,044

240,804

Loss from operations

(61,168)

(79,131)

(133,123)

(188,394)

Other income (expense):

Interest income, net

2,009

3,752

4,583

8,059

Other income (expense), net

145

(4)

477

Loss before income taxes

(59,144)

(75,234)

(128,544)

(179,858)

Provision for (benefit from) income taxes

(41)

Net loss

(59,103)

(75,270)

(128,503)

(179,894)

Other comprehensive loss, net of tax

954

620

Total comprehensive loss

$ (59,103)

$ (74,316)

$ (128,503)

$ (179,274)

Net loss per share of Class A and Class B common stock attributable to common stockholders

Basic (in usd per share)

^[1]

$ (2.32)

$ (3.17)

$ (5.11)

$ (7.68)

Diluted (in usd per share)

^[1]

$ (2.32)

$ (3.17)

$ (5.11)

$ (7.68)

Weighted-average shares used to compute net loss per share

Basic (in shares)

^[1]

25,519,658

23,742,914

25,151,988

23,429,600

Diluted (in shares)

^[1]

25,519,658

23,742,914

25,151,988

23,429,600

Service

Revenue:

Total revenue

$ 38,514

$ 42,766

$ 73,193

$ 96,026

Cost of revenue:

Total cost of revenue

18,801

25,227

36,050

52,172

Product

Revenue:

Total revenue

5,557

7,233

11,292

14,837

Cost of revenue:

Total cost of revenue

$ 2,863

$ 3,043

$ 5,514

$ 6,281

[1]	Amounts have been adjusted to reflect the reverse stock split that became effective on October 16, 2024. Refer to Note 2, “Summary of Significant Accounting Policies” and Note 19, “Subsequent Events,” for further information about the reverse stock split.

Segment Information - Additional Information (Details)	6 Months Ended
Segment Information - Additional Information (Details)	Sep. 30, 2024 reportable_segment
Segment Reporting [Abstract]
Number of reporting segments	2

Revenue (Tables)

6 Months Ended

Sep. 30, 2024

Revenue from Contract with Customer [Abstract]

Schedule of Revenue by Category

The following table presents revenue by category:


	Three Months Ended September 30,								Six Months Ended September 30,
	2024				2023				2024				2023
	Amount		% of Revenue		Amount		% of Revenue		Amount		% of Revenue		Amount		% of Revenue

	(in thousands, except percentages)
Point in Time (1)
Personal genome service (“PGS”)	$	27,652	63	%	$	34,202	68	%	$	52,049	62	%	$	65,961	59	%
Telehealth	4,890		11	%	6,872		14	%	9,929		12	%	15,157		14	%
Consumer services	32,542		74	%	41,074		82	%	61,978		74	%	81,118		73	%
Research services	—		—	%	—		—	%	344		—	%	2,353		2	%
Total	$	32,542	74	%	$	41,074	82	%	$	62,322	74	%	$	83,471	75	%

Over Time (1)
PGS	$	9,515	22	%	$	5,400	11	%	$	17,624	20	%	$	10,670	10	%
Telehealth	1,533		3	%	2,184		4	%	3,141		4	%	4,423		4	%
Consumer services	11,048		25	%	7,584		15	%	20,765		24	%	15,093		14	%
Research services	481		1	%	1,341		3	%	1,398		2	%	12,299		11	%
Total	$	11,529	26	%	$	8,925	18	%	$	22,163	26	%	$	27,392	25	%

Revenue by Category (1)
PGS	$	37,167	84	%	$	39,602	79	%	$	69,673	82	%	$	76,631	69	%
Telehealth	6,423		15	%	9,056		18	%	13,070		16	%	19,580		18	%
Consumer services	43,590		99	%	48,658		97	%	82,743		98	%	96,211		87	%
Research services	481		1	%	1,341		3	%	1,742		2	%	14,652		13	%
Total	$	44,071	100	%	$	49,999	100	%	$	84,485	100	%	$	110,863	100	%

(1)There was no Therapeutics revenue for the three and six months ended September 30, 2024 and 2023.

Schedule of Revenue by Region Based on the Shipping Address of Customers

The following table summarizes revenue by region based on the shipping address of customers:


	Three Months Ended September 30,								Six Months Ended September 30,
	2024				2023				2024				2023
	Amount		% of Revenue		Amount		% of Revenue		Amount		% of Revenue		Amount		% of Revenue

	(in thousands, except percentages)
United States	$	38,671	88	%	$	42,185	84	%	$	73,956	88	%	$	85,511	77	%
United Kingdom	1,968		4	%	4,163		8	%	4,092		5	%	18,518		17	%
Canada	2,402		5	%	2,558		5	%	4,417		5	%	4,728		4	%
Other regions	1,030		3	%	1,093		3	%	2,020		2	%	2,106		2	%
Total	$	44,071	100	%	$	49,999	100	%	$	84,485	100	%	$	110,863	100	%

Leases - Schedule of Future Minimum Lease Payments Related to Company's Operating Lease Liability (Details) $ in Thousands	Sep. 30, 2024 USD ($)
Leases [Abstract]
Remainder of 2025 (Remaining six months)	$ 6,527
2026	15,946
2027	15,472
2028	11,666
2029	12,016
Thereafter	29,414
Total future operating lease payments	91,041
Less: imputed interest	(19,353)
Total operating lease liabilities	$ 71,688

Stockholders' Equity (Tables)

6 Months Ended

Sep. 30, 2024

Equity [Abstract]

Schedule of Common Stock Reserved for Issuance

The Company has the following shares of Class A common stock reserved for future issuance, on an as-if-converted basis:


	September 30, 2024	March 31, 2024
Outstanding stock options	3,134,850	3,536,989
Outstanding restricted stock units	3,401,997	2,202,834
Remaining shares available for future issuance under Amended and Restated 2021 Incentive Equity Plan	3,498,219	5,563,844
Remaining shares available for future issuance under Employee Stock Purchase Plan	580,456	642,263
Total shares of common stock reserved	10,615,522	11,945,930

Equity Incentive Plans and Stock-Based Compensation - Schedule of Restricted Stock Awards Activity under the Equity Incentive Plan (Details) - Restricted Stock Units	6 Months Ended
	Sep. 30, 2024 $ / shares shares
Unvested RSUs
Unvested RSUs, beginning balance (in shares) \| shares	2,203,078
Granted (in shares) \| shares	3,070,895
Vested (in shares) \| shares	(1,276,111)
Cancelled/forfeited (in shares) \| shares	(595,865)
Unvested RSUs, ending balance (in shares) \| shares	3,401,997
Weighted-Average Grant Date Fair Value Per Share
Beginning balance (in usd per share) \| $ / shares	$ 45.86
Granted (in usd per share) \| $ / shares	9.36
Vested (in usd per share) \| $ / shares	26.41
Cancelled/forfeited (in usd per share) \| $ / shares	22.24
Ending balance (in usd per share) \| $ / shares	$ 24.34

Retirement Benefit Plans (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Retirement Benefit Plans (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Retirement Benefits [Abstract]
Employer matching contribution, percent of match			100.00%
Employer matching contribution, percent of employees' gross pay			2.00%
Employer matching contribution			$ 2,300
Contributions cost	$ 600	$ 500	$ 1,100	$ 1,400

Variable Interest Entities (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Recognized revenue	$ 44,071	$ 49,999	$ 84,485	$ 110,863
Variable Interest Entity, Primary Beneficiary
Recognized revenue	$ 900	$ 8,500	$ 1,800	$ 17,500

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Cover - shares	6 Months Ended
Cover - shares	Sep. 30, 2024	Oct. 31, 2024
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Entity File Number	001-39587
Entity Registrant Name	23ANDME HOLDING CO
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	87-1240344
Entity Address, Address Line One	223 N. Mathilda Avenue
Entity Address, City or Town	Sunnyvale
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94086
City Area Code	650
Local Phone Number	938-6300
Title of each class	Class A common stock, $0.0001 par value per share
Trading Symbol(s)	ME
Name of each exchange on which registered	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Central Index Key	0001804591
Current Fiscal Year End Date	--03-31
Document Fiscal Year Focus	2025
Document Fiscal Period Focus	Q2
Amendment flag	false
Class A Common Stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		19,011,874
Class B Common Stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		7,106,123

Stockholders' Equity

6 Months Ended

Sep. 30, 2024

Equity [Abstract]

Stockholders' Equity

Stockholders’ Equity

Common Stock

The Company has authorized Class A common stock and Class B common stock. The rights of the holders of Class A common stock and Class B common stock are identical, except with respect to voting and conversion rights. Holders of Class A common stock are entitled to one vote per share and holders of Class B common stock are entitled to ten votes per share. Each share of Class B common stock is convertible into one share of Class A common stock any time at the option of the holder and is automatically converted into one share of Class A common stock upon transfer (except for certain permitted transfers). Once converted into Class A common stock, the Class B common stock will not be reissued.

Earn-Out Shares

As of September 30, 2024 and March 31, 2024, the Class A common stock included 190,707 shares held by VGAC founders (“Earn-Out Shares”) that are subject to a lock-up of seven years from June 16, 2021, the closing date of the Merger. The lock-up has an early release effective (i) with respect to 50% of the Earn-Out Shares, upon the closing price of the Company’s Class A common stock equaling or exceeding $250.00 per share for any 20 trading days within any 30-trading-day period, and (ii) with respect to the other 50% of the Earn-Out Shares, upon the closing price of the Company’s Class A common stock equaling or exceeding $300.00 per share for any 20 trading days within any 30-trading-day period; provided that the transfer restrictions applicable to the Earn-Out Shares will terminate on the date following the closing date on which the Company completes a liquidation, merger, amalgamation, capital stock exchange, reorganization, or other similar transaction that results in all of the Company’s public stockholders having the right to exchange their shares of Class A common stock for cash, securities, or other property (a “Liquidation Event”), if such Liquidation Event occurs prior to the date that the stock price thresholds referenced in (i) and (ii) are met. As of September 30, 2024, the Company did not meet any earn-out thresholds. The Earn-Out Shares are issued and outstanding Class A common shares that cannot be forfeited, and as such, meet the criteria for equity classification in accordance with ASC 505, Equity.

Reserve for Issuance

The Company has the following shares of Class A common stock reserved for future issuance, on an as-if-converted basis:


	September 30, 2024	March 31, 2024
Outstanding stock options	3,134,850	3,536,989
Outstanding restricted stock units	3,401,997	2,202,834
Remaining shares available for future issuance under Amended and Restated 2021 Incentive Equity Plan	3,498,219	5,563,844
Remaining shares available for future issuance under Employee Stock Purchase Plan	580,456	642,263
Total shares of common stock reserved	10,615,522	11,945,930

At-the-Market (“ATM”) Offering

On February 6, 2023, the Company entered into a sales agreement with Cowen and Company, LLC (“Cowen”), as sales agent, pursuant to which the Company may sell shares of its Class A common stock for an aggregate up to $150.0 million under at-the-market offering program (the “ATM program”). The Company will pay Cowen a commission of 3.0% of the gross proceeds for the Class A common stock sold through the ATM program. As of September 30, 2024, the Company had not made any sales under the ATM program. The sales agreement will terminate upon the earliest of (a) the sale of the maximum number or amount of the shares permitted to be sold under the sales agreement and (b) the termination of the sales agreement by the parties thereto.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

+ Details

Equity Incentive Plans and Stock-Based Compensation - Schedule of Share Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 19,486	$ 23,741	$ 41,063	$ 74,840
Secondary Sale Transaction \| Cost of revenue \| Service
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	871	1,041	1,847	3,099
Secondary Sale Transaction \| Cost of revenue \| Product
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	442	456	835	870
Secondary Sale Transaction \| Research and development
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	8,565	10,938	19,636	22,630
Secondary Sale Transaction \| Sales and marketing
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	2,155	2,016	4,614	3,734
Secondary Sale Transaction \| General and administrative
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	7,150	9,290	13,828	43,866
Secondary Sale Transaction \| General and administrative \| Former Lemonaid Officer
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense				22,000
Secondary Sale Transaction \| Restructuring and other charges
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 303	$ 0	$ 303	$ 641

Balance Sheet Components

6 Months Ended

Sep. 30, 2024

Balance Sheet Related Disclosures [Abstract]

Balance Sheet Components

Prepaid Expense and Other Current Assets

Prepaid expense and other current assets consisted of the following:


	September 30, 2024		March 31, 2024
	(in thousands)
Prepaid expenses	$	12,894	$	9,296
Insurance recovery receivable	22,633		2,188
Other receivables	1,751		3,563
Other current assets	2,372		1,794
Prepaid expenses and other current assets	$	39,650	$	16,841

Property and Equipment, Net

Property and equipment, net consisted of the following:


	September 30, 2024		March 31, 2024
	(in thousands)
Computer equipment and software	$	7,392	$	7,485
Laboratory equipment and software	51,363		51,635
Furniture and office equipment	8,937		8,929
Leasehold improvements	41,467		41,180
Capitalized asset retirement obligations	853		853
Property and equipment, gross	110,012		110,082
Less: accumulated depreciation and amortization	(85,198)		(81,731)
Property and equipment, net	$	24,814	$	28,351

Depreciation and amortization expense was $2.0 million and $3.0 million for the three months ended September 30, 2024 and 2023, respectively, and $4.0 million and $6.0 million for the six months ended September 30,

2024 and 2023, respectively. There were no impairments to property and equipment for the three and six months ended September 30, 2024 and 2023.

Operating Lease Right-Of-Use Assets, Net

Operating lease right-of-use assets, net consisted of the following:


	September 30, 2024		March 31, 2024
	(in thousands)
Operating lease right-of-use assets	$	85,166	$	85,166
Less: accumulated amortization	(40,062)		(36,272)
Operating lease right-of-use assets, net	$	45,104	$	48,894

Internal-Use Software, Net

Internal-use software, net consisted of the following:


	September 30, 2024		March 31, 2024
	(in thousands)
Capitalized internal-use software	$	39,296	$	35,918
Less: accumulated amortization	(18,817)		(15,402)
Internal-use software, net	$	20,479	$	20,516

The Company capitalized $3.2 million and $3.4 million in internal-use software during the three months ended September 30, 2024 and 2023, respectively, and $4.5 million and $6.8 million in internal-use software during the six months ended September 30, 2024 and 2023, respectively. In addition, the Company wrote off $1.1 million of internal-use software during the three months ended September 30, 2023 related to the disposition of Lemonaid Health Limited, refer to Note 17 “Disposition of Subsidiary,” for additional information.

Amortization of internal-use software was $1.6 million and $1.3 million for the three months ended September 30, 2024 and 2023, respectively, and $3.4 million and $2.5 million for the six months ended September 30, 2024 and 2023, respectively. Impairment to internal-use software was $1.2 million and nil for the three and six months ended September 30, 2024 and 2023, respectively.

Intangible Assets, Net

Intangible assets, net consisted of the following:


	September 30, 2024
	Weighted Average Remaining Useful Life (Years)	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
	(in thousands, except years)
Customer relationships	0.0	$	14,900	$	(14,900)	$	—
Partnerships	7.1	9,000		(2,625)		6,375
Trademark	2.1	11,000		(6,417)		4,583
Developed technology	4.1	24,100		(10,042)		14,058
Non-compete agreements	2.1	2,800		(1,633)		1,167
Patents	4.0	5,500		(2,388)		3,112
Total intangible assets		$	67,300	$	(38,005)	$	29,295


	March 31, 2024
	Weighted Average Remaining Useful Life (Years)	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
	(in thousands, except years)
Customer relationships	0.0	$	14,900	$	(14,900)	$	—
Partnerships	7.6	9,000		(2,175)		6,825
Trademark	2.6	11,000		(5,317)		5,683
Developed technology	4.6	24,100		(8,320)		15,780
Non-compete agreements	2.6	2,800		(1,353)		1,447
Patents	4.5	5,500		(1,980)		3,520
Total intangible assets		$	67,300	$	(34,045)	$	33,255

Amortization expense for intangible assets was $2.0 million and $3.8 million for the three months ended September 30, 2024 and 2023, respectively, and $4.0 million and $7.7 million for six months ended September 30, 2024 and 2023, respectively. There was no impairment to intangible assets during the three and six months ended September 30, 2024 and 2023.

Estimated future amortization expense of the identified intangible assets as of September 30, 2024 was as follows:


	Estimated Amortization
	(in thousands)
Fiscal years ending March 31,
Remainder of 2025 (Remaining six months)	$	3,960
2026	7,919
2027	6,769
2028	5,006
2029	3,175
Thereafter	2,466
Total estimated future amortization expense	$	29,295

Accrued Expense and Other Current Liabilities

Accrued expense and other current liabilities consisted of the following:


	September 30, 2024		March 31, 2024
	(in thousands)
Accrued payables	$	8,660	$	9,697
Accrued settlement and legal expenses	34,525		3,260
Accrued compensation and benefits	3,235		4,266
Accrued vacation	6,643		7,221
Accrued bonus	7,696		7,420
Accrued clinical expenses	5,467		9,291
Accrued taxes and other	1,102		1,108
Total accrued expenses and other current liabilities	$	67,328	$	42,263

Retirement Benefit Plans	6 Months Ended
Retirement Benefit Plans	Sep. 30, 2024
Retirement Benefits [Abstract]
Retirement Benefit Plans	Retirement Benefit Plans The Company has established a 401(k) retirement plan that allows participating employees in the U.S. to contribute as defined by the terms of the plan and subject to the limitations under Section 401(k) of the Code. The Company matches the greater of 100% of the first 2% or 100% of the first $2,300 (subject to annual compensation and contribution limits) of employee contributions. The Company recognized matching contributions cost of $0.6 million and $0.5 million for the three months ended September 30, 2024 and 2023, respectively, and $1.1 million and $1.4 million for the six months ended September 30, 2024 and 2023, respectively.

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 70
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480794/715-70-50-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480482/715-20-55-17

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (q)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/715/tableOfContent

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (o)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (p)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 60
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480266/715-60-50-3

+ Details

Subsequent Events (Details) $ in Thousands				3 Months Ended			6 Months Ended
Subsequent Events (Details) $ in Thousands	Oct. 16, 2024 shares	Oct. 07, 2024	Aug. 26, 2024	Dec. 31, 2024 USD ($)	Sep. 30, 2024 USD ($) shares	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) shares	Sep. 30, 2023 USD ($)	Oct. 29, 2024 independent_director	Mar. 31, 2024 shares
Subsequent Event [Line Items]
Percentage of total voting power of outstanding stock			67.00%
Restructuring and other charges					$ 2,242	$ 2,654	$ 2,242	$ 6,871
Employee Severance
Subsequent Event [Line Items]
Restructuring and other charges					$ 1,900	$ 2,700	$ 1,900	$ 6,300
Subsequent Event
Subsequent Event [Line Items]
Reverse stock split	0.05	0.05
Number of independent directors appointed \| independent_director									3
Subsequent Event \| Forecast \| November Reduction In Force
Subsequent Event [Line Items]
Restructuring and other charges				$ 11,700
Subsequent Event \| Forecast \| November Reduction In Force \| Employee Severance
Subsequent Event [Line Items]
Restructuring and other charges				9,300
Subsequent Event \| Forecast \| November Reduction In Force \| Equity Compensation Charges
Subsequent Event [Line Items]
Restructuring and other charges				$ 2,400
Class A Common Stock
Subsequent Event [Line Items]
Common stock, shares authorized (in shares) \| shares					1,140,000,000		1,140,000,000			1,140,000,000
Class A Common Stock \| Subsequent Event
Subsequent Event [Line Items]
Common stock, shares authorized (in shares) \| shares	1,140,000,000
Class B Common Stock
Subsequent Event [Line Items]
Common stock, shares authorized (in shares) \| shares					350,000,000		350,000,000			350,000,000
Class B Common Stock \| Subsequent Event
Subsequent Event [Line Items]
Common stock, shares authorized (in shares) \| shares	350,000,000
Minimum
Subsequent Event [Line Items]
Reverse stock split			0.200
Maximum
Subsequent Event [Line Items]
Reverse stock split			0.0333

Balance Sheet Components - Schedule of Internal Use Software (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Mar. 31, 2024
Balance Sheet Related Disclosures [Abstract]
Capitalized internal-use software	$ 39,296	$ 35,918
Less: accumulated amortization	(18,817)	(15,402)
Internal-use software, net	$ 20,479	$ 20,516

Stockholders' Equity - Schedule of Common Stock Reserved for Issuance (Details) - shares	Sep. 30, 2024	Mar. 31, 2024
Class of Stock [Line Items]
Outstanding stock options (in shares)	3,134,850	3,536,989
Total shares of common stock reserved (in shares)	10,615,522	11,945,930
2021 Incentive Equity Plan
Class of Stock [Line Items]
Remaining shares available for future issuance under Amended and Restated 2021 Incentive Equity Plan (in shares)	3,498,219	5,563,844
Employee Stock Purchase Plan
Class of Stock [Line Items]
Remaining shares available for future issuance under Employee Stock Purchase Plan (in shares)	580,456	642,263
Restricted Stock Units
Class of Stock [Line Items]
Outstanding restricted stock units (in shares)	3,401,997	2,202,834

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef
-Topic 272
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483014/272-10-45-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 272
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482987/272-10-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(2)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(2)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

+ Details

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net loss	$ (128,503)	$ (179,894)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	7,948	13,714
Amortization and impairment of internal-use software	4,586	2,514
Stock-based compensation expense	41,063	74,840
Gain on disposal of property and equipment	(55)	(5)
Loss on disposition of Lemonaid Health Limited	0	2,026
Other operating activities	0	(504)
Changes in operating assets and liabilities:
Accounts receivable, net (includes related party amounts of $1 and $19 for the six months ended September 30, 2024 and 2023, respectively)	2,878	396
Inventories	(2,381)	(4,733)
Deferred cost of revenue	(950)	(406)
Prepaid expenses and other current assets	(174)	(2,433)
Operating lease right-of-use assets	3,790	3,529
Other assets	381	664
Accounts payable (includes related party amounts of $(3,809) and $(3,186) for the six months ended September 30, 2024 and 2023, respectively)	(5,063)	(3,951)
Accrued expenses and other current liabilities (includes related party amounts of $(4,822) and $4,993 for the six months ended September 30, 2024 and 2023, respectively)	1,899	(5,674)
Deferred revenue (includes related party amounts of $661 and $(11,753) for the six months ended September 30, 2024 and 2023, respectively)	(5,076)	(22,237)
Operating lease liabilities	(4,826)	(4,255)
Other liabilities	283	(65)
Net cash used in operating activities	(84,200)	(126,474)
Cash flows from investing activities:
Purchases of property and equipment	(566)	(715)
Proceeds from sale of property and equipment	159	5
Capitalized internal-use software costs	(3,449)	(4,758)
Net cash used in investing activities	(3,856)	(5,468)
Cash flows from financing activities:
Proceeds from exercise of stock options	58	473
Proceeds from issuance of common stock under employee stock purchase plan	331	1,411
Payments of deferred offering costs	(2)	(263)
Payments for taxes related to net share settlement of equity awards	(118)	(142)
Net cash provided by financing activities	269	1,479
Net decrease in cash, cash equivalents and restricted cash	(87,787)	(130,463)
Cash, cash equivalents and restricted cash—beginning of period	224,861	395,222
Cash, cash equivalents and restricted cash—end of period	137,074	264,759
Supplemental disclosures of non-cash investing and financing activities:
Purchases of property and equipment included in accounts payable and accrued expenses	85	26
Stock-based compensation capitalized for internal-use software costs	1,099	2,089
Reconciliation of cash, cash equivalents, and restricted cash within the condensed consolidated balance sheets to the amounts shown in the condensed consolidated statements of cash flows above:
Cash and cash equivalents	126,601	256,386
Restricted cash, current	1,499	1,399
Restricted cash, noncurrent	8,974	6,974
Total cash, cash equivalents and restricted cash	$ 137,074	$ 264,759

Disposition of Subsidiary (Details) - USD ($)	3 Months Ended		6 Months Ended
Disposition of Subsidiary (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Disposal Groups, Including Discontinued Operations [Line Items]
Loss on disposition of Lemonaid Health Limited and transaction-related costs	$ 0	$ 2,127,000	$ 0	$ 2,375,000
Disposal Group, Disposed of by Sale, Not Discontinued Operations \| Lemonaid Health Limited
Disposal Groups, Including Discontinued Operations [Line Items]
Loss on disposition of Lemonaid Health Limited and transaction-related costs	$ 0	$ 2,100,000	$ 0	$ 2,400,000

Segment Information - Schedule of Customers Accounting for 10% or More of Segment Revenues (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Segment Reporting Information [Line Items]
Recognized revenue	$ 44,071	$ 49,999	$ 84,485	$ 110,863
% of Revenue			100.00%	100.00%
Customer C \| Consumer and Research Services \| Revenue \| Customer Concentration Risk
Segment Reporting Information [Line Items]
Recognized revenue	$ 11,586	$ 13,040	$ 19,163	$ 22,751
% of Revenue	26.00%	26.00%	23.00%	21.00%
Customer B \| Consumer and Research Services \| Revenue \| Customer Concentration Risk
Segment Reporting Information [Line Items]
Recognized revenue				$ 11,753
% of Revenue				11.00%

- Definition

+ References

+ Details

Balance Sheet Components - Schedule of Intangible Assets, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Mar. 31, 2024
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 67,300	$ 67,300
Accumulated Amortization	(38,005)	(34,045)
Total estimated future amortization expense	$ 29,295	$ 33,255
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Weighted Average Remaining Useful Life (Years)	0 years	0 years
Gross Carrying Amount	$ 14,900	$ 14,900
Accumulated Amortization	(14,900)	(14,900)
Total estimated future amortization expense	$ 0	$ 0
Partnerships
Finite-Lived Intangible Assets [Line Items]
Weighted Average Remaining Useful Life (Years)	7 years 1 month 6 days	7 years 7 months 6 days
Gross Carrying Amount	$ 9,000	$ 9,000
Accumulated Amortization	(2,625)	(2,175)
Total estimated future amortization expense	$ 6,375	$ 6,825
Trademark
Finite-Lived Intangible Assets [Line Items]
Weighted Average Remaining Useful Life (Years)	2 years 1 month 6 days	2 years 7 months 6 days
Gross Carrying Amount	$ 11,000	$ 11,000
Accumulated Amortization	(6,417)	(5,317)
Total estimated future amortization expense	$ 4,583	$ 5,683
Developed technology
Finite-Lived Intangible Assets [Line Items]
Weighted Average Remaining Useful Life (Years)	4 years 1 month 6 days	4 years 7 months 6 days
Gross Carrying Amount	$ 24,100	$ 24,100
Accumulated Amortization	(10,042)	(8,320)
Total estimated future amortization expense	$ 14,058	$ 15,780
Non-compete agreements
Finite-Lived Intangible Assets [Line Items]
Weighted Average Remaining Useful Life (Years)	2 years 1 month 6 days	2 years 7 months 6 days
Gross Carrying Amount	$ 2,800	$ 2,800
Accumulated Amortization	(1,633)	(1,353)
Total estimated future amortization expense	$ 1,167	$ 1,447
Patents
Finite-Lived Intangible Assets [Line Items]
Weighted Average Remaining Useful Life (Years)	4 years	4 years 6 months
Gross Carrying Amount	$ 5,500	$ 5,500
Accumulated Amortization	(2,388)	(1,980)
Total estimated future amortization expense	$ 3,112	$ 3,520

Revenue - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Mar. 31, 2024
Disaggregation of Revenue [Line Items]
Revenue recognized from unreturned kits	$ 5.4	$ 4.3	$ 9.4	$ 8.9
Contract assets	$ 0.0		$ 0.0		$ 0.0
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-10-01
Disaggregation of Revenue [Line Items]
Revenue to be recognized, percentage	86.00%		86.00%
Remaining performance obligation, expected timing of satisfaction, period	12 months		12 months
Consumer services
Disaggregation of Revenue [Line Items]
Deferred revenue for customer services	$ 47.2		$ 47.2		52.3
Revenue recognized	10.8		32.4
Research services
Disaggregation of Revenue [Line Items]
Deferred revenue for customer services	22.6		22.6		22.5
Revenue recognized	0.4		1.4
Remaining performance obligations	26.7		26.7
Research services \| Related Party
Disaggregation of Revenue [Line Items]
Deferred revenue for customer services	21.7		21.7		$ 21.0
Revenue recognized	$ 0.3		$ 0.5

Leases (Tables)

6 Months Ended

Sep. 30, 2024

Leases [Abstract]

Schedule of Future Minimum Lease Payments Related to Company's Operating Lease Liability

As of September 30, 2024, the future minimum lease payments included in the measurement of the Company’s operating lease liabilities were as follows:


	September 30, 2024
	(in thousands)
Fiscal years ending March 31,
Remainder of 2025 (Remaining six months)	$	6,527
2026	15,946
2027	15,472
2028	11,666
2029	12,016
Thereafter	29,414
Total future operating lease payments	91,041
Less: imputed interest	(19,353)
Total operating lease liabilities	$	71,688

Segment Information (Tables)

6 Months Ended

Sep. 30, 2024

Segment Reporting [Abstract]

Schedule of Revenue and Adjusted EBITDA by Segment

The Company’s revenue and Adjusted EBITDA by segment is as follows:


	Three Months Ended September 30,				Six Months Ended September 30,
	2024		2023		2024		2023
	(in thousands)
Segment Revenue: (1)
Consumer and Research Services	$	44,071	$	49,999	$	84,485	$	110,863
Total revenue	$	44,071	$	49,999	$	84,485	$	110,863
Segment Adjusted EBITDA:
Consumer and Research Services Adjusted EBITDA	$	(8,633)	$	(6,673)	$	(17,474)	$	(12,275)
Therapeutics Adjusted EBITDA	(11,975)		(26,224)		(24,392)		(57,363)
Unallocated Corporate	(12,804)		(12,156)		(26,708)		(25,215)
Total Adjusted EBITDA	$	(33,412)	$	(45,053)	$	(68,574)	$	(94,853)
Reconciliation of net loss to Adjusted EBITDA:
Net loss	$	(59,103)	$	(75,270)	$	(128,503)	$	(179,894)
Adjustments:
Interest income, net	(2,009)		(3,752)		(4,583)		(8,059)
Other (income) expense, net	(15)		(145)		4		(477)
Provision for (benefit from) income taxes	(41)		36		(41)		36
Depreciation and amortization	4,972		4,474		8,983		8,951
Amortization of acquired intangible assets	1,775		3,638		3,551		7,277

Stock-based compensation expense	19,486		23,741		41,063		74,840
Loss on disposition of Lemonaid Health Limited and transaction-related costs(2)	—		2,127		—		2,375
Litigation settlement cost	—		98		—		98

Cyber security incident expenses, net of probable insurance recoveries (3)	1,523		—		10,952		—
Total Adjusted EBITDA	$	(33,412)	$	(45,053)	$	(68,574)	$	(94,853)

(1)There was no Therapeutics revenue for the three and six months ended September 30, 2024 and 2023.

(2)Refer to Note 17, “Disposition of Subsidiary” for additional information.

(3)Refer to Note 11, “Cyber Security Incident” for additional information.

Schedule of Customers Accounting for 10% or More of Segment Revenues

Customers accounting for 10% or more of segment revenues were as follows:


	Three Months Ended September 30,								Six Months Ended September 30,

	2024				2023				2024				2023

	(in thousands)
Consumer and Research Services Segment Revenue:
Customer C (1)(2)	$	11,586	26	%	$	13,040	26	%	$	19,163	23	%	$	22,751	21	%
Customer B (3)	*		*		*		*		*		*		$	11,753	11	%

•less than 10%

(1)Customer C is a reseller.

(2)Customer C revenues are primarily in the United States.

(3)Customer B revenues are in the U.K.

Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands

Sep. 30, 2024

Mar. 31, 2024

Current assets:

Cash and cash equivalents

$ 126,601

$ 216,488

Restricted cash

1,499

1,399

Accounts receivable, net

446

3,324

Inventories

14,846

12,465

Deferred cost of revenue

5,742

4,792

Prepaid expenses and other current assets

39,650

16,841

Total current assets

188,784

255,309

Property and equipment, net

24,814

28,351

Operating lease right-of-use assets

45,104

48,894

Restricted cash, noncurrent

8,974

6,974

Internal-use software, net

20,479

20,516

Intangible assets, net

29,295

33,255

Other assets

1,486

1,868

Total assets

318,936

395,167

Current liabilities:

Accounts payable (includes related party amounts of nil and $3,809, respectively)

6,486

11,571

Accrued expenses and other current liabilities (includes related party amounts of $1,930 and $6,752, respectively)

67,328

42,263

Deferred revenue (includes related party amounts of $21,659 and $10,999, respectively)

69,751

64,827

Operating lease liabilities

9,266

8,670

Total current liabilities

152,831

127,331

Deferred revenue, noncurrent (includes related party amounts of nil and $10,000, respectively)

10,000

Operating lease liabilities, noncurrent

62,422

67,845

Other liabilities

1,754

1,471

Total liabilities

217,007

206,647

Commitments and contingencies (Note 11)

Stockholders’ equity

Preferred stock - par value $0.0001, 10,000,000 shares authorized as of September 30, 2024 and March 31, 2024; zero shares issued and outstanding as of September 30, 2024 and March 31, 2024

Common stock, par value $0.0001 - Class A shares, 1,140,000,000 shares authorized, 17,514,204 and 16,169,741 shares issued and outstanding as of September 30, 2024 and March 31, 2024, respectively; Class B shares, 350,000,000 shares authorized, 8,322,160 and 8,336,229 shares issued and outstanding as of September 30, 2024 and March 31, 2024, respectively

^[1]

Additional paid-in capital

^[1]

2,403,517

2,361,606

Accumulated deficit

(2,301,591)

(2,173,088)

Total stockholders’ equity

101,929

188,520

Total liabilities and stockholders’ equity

$ 318,936

$ 395,167

[1]	Amounts have been adjusted to reflect the reverse stock split that became effective on October 16, 2024. Refer to Note 2, “Summary of Significant Accounting Policies” and Note 19, “Subsequent Events,” for further information about the reverse stock split.

Revenue - Schedule of Revenue by Category (Details) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Disaggregation of Revenue [Line Items]
Amount	$ 44,071,000	$ 49,999,000	$ 84,485,000	$ 110,863,000
% of Revenue			100.00%	100.00%
Personal genome service (“PGS”)
Disaggregation of Revenue [Line Items]
Amount	37,167,000	39,602,000	$ 69,673,000	$ 76,631,000
Personal genome service (“PGS”) \| Point in Time
Disaggregation of Revenue [Line Items]
Amount	27,652,000	34,202,000	52,049,000	65,961,000
Personal genome service (“PGS”) \| Over Time
Disaggregation of Revenue [Line Items]
Amount	9,515,000	5,400,000	17,624,000	10,670,000
Telehealth
Disaggregation of Revenue [Line Items]
Amount	6,423,000	9,056,000	13,070,000	19,580,000
Telehealth \| Point in Time
Disaggregation of Revenue [Line Items]
Amount	4,890,000	6,872,000	9,929,000	15,157,000
Telehealth \| Over Time
Disaggregation of Revenue [Line Items]
Amount	1,533,000	2,184,000	3,141,000	4,423,000
Consumer services
Disaggregation of Revenue [Line Items]
Amount	43,590,000	48,658,000	82,743,000	96,211,000
Consumer services \| Point in Time
Disaggregation of Revenue [Line Items]
Amount	32,542,000	41,074,000	61,978,000	81,118,000
Consumer services \| Over Time
Disaggregation of Revenue [Line Items]
Amount	11,048,000	7,584,000	20,765,000	15,093,000
Research services
Disaggregation of Revenue [Line Items]
Amount	481,000	1,341,000	1,742,000	14,652,000
Research services \| Point in Time
Disaggregation of Revenue [Line Items]
Amount	0	0	344,000	2,353,000
Research services \| Over Time
Disaggregation of Revenue [Line Items]
Amount	481,000	1,341,000	1,398,000	12,299,000
Service
Disaggregation of Revenue [Line Items]
Amount	38,514,000	42,766,000	73,193,000	96,026,000
Service \| Point in Time
Disaggregation of Revenue [Line Items]
Amount	32,542,000	41,074,000	62,322,000	83,471,000
Service \| Over Time
Disaggregation of Revenue [Line Items]
Amount	11,529,000	8,925,000	22,163,000	27,392,000
Therapeutics
Disaggregation of Revenue [Line Items]
Amount	$ 0	$ 0	$ 0	$ 0
Product Concentration Risk \| Revenue
Disaggregation of Revenue [Line Items]
% of Revenue	100.00%	100.00%	100.00%	100.00%
Product Concentration Risk \| Revenue \| Personal genome service (“PGS”)
Disaggregation of Revenue [Line Items]
% of Revenue	84.00%	79.00%	82.00%	69.00%
Product Concentration Risk \| Revenue \| Personal genome service (“PGS”) \| Point in Time
Disaggregation of Revenue [Line Items]
% of Revenue	63.00%	68.00%	62.00%	59.00%
Product Concentration Risk \| Revenue \| Personal genome service (“PGS”) \| Over Time
Disaggregation of Revenue [Line Items]
% of Revenue	22.00%	11.00%	20.00%	10.00%
Product Concentration Risk \| Revenue \| Telehealth
Disaggregation of Revenue [Line Items]
% of Revenue	15.00%	18.00%	16.00%	18.00%
Product Concentration Risk \| Revenue \| Telehealth \| Point in Time
Disaggregation of Revenue [Line Items]
% of Revenue	11.00%	14.00%	12.00%	14.00%
Product Concentration Risk \| Revenue \| Telehealth \| Over Time
Disaggregation of Revenue [Line Items]
% of Revenue	3.00%	4.00%	4.00%	4.00%
Product Concentration Risk \| Revenue \| Consumer services
Disaggregation of Revenue [Line Items]
% of Revenue	99.00%	97.00%	98.00%	87.00%
Product Concentration Risk \| Revenue \| Consumer services \| Point in Time
Disaggregation of Revenue [Line Items]
% of Revenue	74.00%	82.00%	74.00%	73.00%
Product Concentration Risk \| Revenue \| Consumer services \| Over Time
Disaggregation of Revenue [Line Items]
% of Revenue	25.00%	15.00%	24.00%	14.00%
Product Concentration Risk \| Revenue \| Research services
Disaggregation of Revenue [Line Items]
% of Revenue	1.00%	3.00%	2.00%	13.00%
Product Concentration Risk \| Revenue \| Research services \| Point in Time
Disaggregation of Revenue [Line Items]
% of Revenue	0.00%	0.00%	0.00%	2.00%
Product Concentration Risk \| Revenue \| Research services \| Over Time
Disaggregation of Revenue [Line Items]
% of Revenue	1.00%	3.00%	2.00%	11.00%
Product Concentration Risk \| Revenue \| Service \| Point in Time
Disaggregation of Revenue [Line Items]
% of Revenue	74.00%	82.00%	74.00%	75.00%
Product Concentration Risk \| Revenue \| Service \| Over Time
Disaggregation of Revenue [Line Items]
% of Revenue	26.00%	18.00%	26.00%	25.00%

Equity Incentive Plans and Stock-Based Compensation (Tables)

6 Months Ended

Sep. 30, 2024

Share-Based Payment Arrangement [Abstract]

Schedule of Stock Option Activity and Activity Regarding Shares Available for Grant

Stock option activity and activity regarding shares available for grant under the Second A&R Plan are as follows:


	Options Outstanding
	Outstanding Stock Options	Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value

	(in thousands, except share, years, and per share data)
Balance as of March 31, 2024	3,537,668	$	73.62	5.1	$	306
Granted	88,615	$	6.82
Exercised	(6,889)	$	8.46
Canceled/forfeited/expired	(484,544)	$	86.04
Balance as of September 30, 2024	3,134,850	$	69.95	5.0	$	43
Vested and exercisable as of September 30, 2024	2,457,428	$	78.52	4.1	$	31

Schedule of Weighted Average Black-Scholes Assumptions

The weighted average Black-Scholes assumptions used to value stock options at the grant dates are as follows:


	Three Months Ended September 30,								Six Months Ended September 30,
	2024				2023				2024				2023
	Min		Max		Min		Max		Min		Max		Min		Max
Expected term (years)	6.0		6.0		5.8		6.0		6.0		6.0		5.8		6.0
Expected volatility range	75	%	75	%	78	%	79	%	75	%	75	%	78	%	79	%
Expected weighted-average volatility	75%				79%				75%				79%
Risk-free interest rate	3.5	%	3.5	%	4.4	%	4.4	%	3.5	%	3.5	%	3.6	%	4.4	%
Expected dividend yield	—		—		—		—		—		—		—		—


	Three Months Ended September 30,								Six Months Ended September 30,
	2024				2023				2024				2023
	Min		Max		Min		Max		Min		Max		Min		Max
Expected term (years)	0.5		1.0		0.5		1.0		0.5		1.0		0.5		1.0
Expected volatility	76	%	77	%	67	%	73	%	76	%	77	%	67	%	73	%
Expected weighted-average volatility	76%				70%				76%				70%
Risk-free interest rate	4.4	%	4.8	%	5.4	%	5.5	%	4.4	%	4.8	%	5.4	%	5.5	%
Expected dividend yield	—		—		—		—		—		—		—		—

Schedule of Restricted Stock Awards Activity under the Equity Incentive Plan

The following table summarizes the RSU activity under the equity incentive plans and related information:


	Unvested RSUs	Weighted-Average Grant Date Fair Value Per Share
Balance as of March 31, 2024	2,203,078	$	45.86
Granted	3,070,895	$	9.36
Vested	(1,276,111)	$	26.41
Canceled/forfeited	(595,865)	$	22.24
Balance as of September 30, 2024	3,401,997	$	24.34

Schedule of Share Based Compensation Expense

Total stock-based compensation expense, including stock-based compensation expense related to awards classified as liabilities, was included in costs and expenses as follows:


	Three Months Ended September 30,				Six Months Ended September 30,
	2024		2023		2024		2023
	(in thousands)
Cost of service revenue	$	871	$	1,041	$	1,847	$	3,099
Cost of product revenue	442		456		835		870
Research and development	8,565		10,938		19,636		22,630
Sales and marketing	2,155		2,016		4,614		3,734
General and administrative (1)	7,150		9,290		13,828		43,866
Restructuring and other charges	303		—		303		641
Total stock-based compensation expense	$	19,486	$	23,741	$	41,063	$	74,840

(1)Includes $22.0 million of stock-based compensation charges related to the termination of a Former Lemonaid Officer during the six months ended September 30, 2023.

Equity Incentive Plans and Stock-Based Compensation - Additional Information (Details)							1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	Oct. 16, 2024 shares	Oct. 07, 2024	Aug. 26, 2024	Jun. 05, 2024 tradingDay	Sep. 06, 2023	Jun. 30, 2023 USD ($) officer	Nov. 30, 2021 USD ($) stockholder shares	Sep. 30, 2024 USD ($) nonemployee_Director shares	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) nonemployee_Director $ / shares shares	Sep. 30, 2023 USD ($) $ / shares shares	Mar. 31, 2024 USD ($)	Sep. 17, 2024 nonemployee_Director
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total stock-based compensation expense								$ 19,486,000	$ 23,741,000	$ 41,063,000	$ 74,840,000
Weighted-average grant date fair values of options granted (in usd per share) \| $ / shares										$ 4.61	$ 17,400,000
Intrinsic value of vested options exercised										$ 0	$ 1,000,000.0
Unrecognized stock-based compensation cost								17,400,000		$ 17,400,000
Weighted average period over which unrecognized compensation is expected to be recognized										2 years 1 month 6 days
Lemonaid Health, Inc.
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period							4 years
Common stock granted subject to vest, weighted average grant date fair value							$ 43,900,000
Former officers terminated \| officer						1
Lemonaid Health, Inc. \| Former Lemonaid Officer
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized stock-based compensation cost								0		$ 0
Lemonaid Health, Inc. \| Former Lemonaid Officer \| General and administrative
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total stock-based compensation expense								0	400,000	0	25,100,000
Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Reverse stock split			0.200
Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Reverse stock split			0.0333
Outstanding stock options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Tax benefit recognized from stock option exercises								0	0	$ 0	0
Outstanding stock options \| Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period					3 years
Outstanding stock options \| Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period					4 years
Unvested restricted stock units
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Granted (in shares) \| shares										3,070,895
Weighted average period over which unrecognized compensation is expected to be recognized										2 years 4 months 24 days
Unrecognized stock-based compensation cost								$ 73,600,000		$ 73,600,000
Unvested restricted stock units \| Lemonaid Health, Inc. \| Former Lemonaid Officer \| General and administrative
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total stock-based compensation expense						$ 22,000,000.0
Subsequent Event
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Reverse stock split	0.05	0.05
Class A Common Stock \| Lemonaid Health, Inc.
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock granted subject to vest (in shares) \| shares							187,352
Class A Common Stock \| Lemonaid Health, Inc. \| Former Lemonaid Officer
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Former stockholders who were granted shares \| stockholder							2
A&R Plan \| Class A Common Stock \| Subsequent Event
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares authorized (in shares) \| shares	10,034,656
Second A And R Plan
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Percentage of shares automatically added annually					5.00%
Non-employee directors, electing to defer settlement of RSUs \| nonemployee_Director													2
Non-employee directors, eligible to participate in the program \| nonemployee_Director								0		0
Second A And R Plan \| Outstanding stock options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based compensation terms of award					Options have a contractual life of up to ten years. The exercise price of a stock option shall not be less than 100% of the estimated fair value of the shares on the date of grant, as determined by the Board of Directors.
Share-based payment award, expiration period					10 years
Exercise price of stock options as a percentage of fair value of shares					100.00%
Number of shares of common stock received for each option exercised					1
Second A And R Plan \| Unvested restricted stock units \| Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period					1 year
Second A And R Plan \| Unvested restricted stock units \| Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period					4 years
Second A And R Plan \| Class A Common Stock \| Subsequent Event
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Reverse stock split	0.05
Annual Incentive Plan \| Unvested restricted stock units
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Performance period												1 year
Granted (in shares) \| shares								607,222
Total stock-based compensation expense								$ 2,900,000	$ 2,400,000	$ 7,000,000.0	$ 6,800,000
Other current liabilities for awards								$ 7,000,000.0		$ 7,000,000.0		$ 6,500,000
Annual Incentive Plan \| Class A Common Stock
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Days preceding date of payment \| tradingDay				20
ESPP \| Subsequent Event
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares authorized (in shares) \| shares	580,456
ESPP \| Subsequent Event \| Employee Stock
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock issued and outstanding, percentage	1.00%
Potential annual increase in shares reserved for future issuance (in shares) \| shares	250,000
A And R ESPP
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted average grant date fair value (in usd per share) \| $ / shares										$ 2.52	$ 8.78
A And R ESPP \| Employee Stock
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
ESPP concurrent offering period										12 months
ESPP successive purchase period										6 months
A And R ESPP \| Class A Common Stock
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Average exercise price (in usd per share) \| $ / shares										$ 5.35	$ 18.70
A And R ESPP \| Class A Common Stock \| Employee Stock
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Issuance of common stock under employee stock purchase plan (in shares) \| shares										61,807	75,472,000,000
A And R ESPP \| Class A Common Stock \| Subsequent Event
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Reverse stock split	0.05

Collaborations (Details)	1 Months Ended		3 Months Ended		6 Months Ended		12 Months Ended
Collaborations (Details)	Oct. 31, 2023 program	Jul. 31, 2018	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Mar. 31, 2024 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue			$ 44,071,000	$ 49,999,000	$ 84,485,000	$ 110,863,000
Cost of revenue			21,664,000	28,270,000	41,564,000	58,453,000
G S K
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration agreement, period		4 years
G S K \| Related Party
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue			0	1,100,000	0	11,800,000
Cost of revenue			0	0	0	0
Research and development expense, net			(400,000)		200,000
Research and development expense				4,900,000		8,200,000
Accounts payable, accrued expenses and other current liabilities			1,900,000		1,900,000		$ 10,600,000
G S K 2023 Amendment
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from license fees received							20,000,000
License for data access, expiration period	1 year
Deferred revenue			20,000,000		20,000,000
Programs, opted-out of cost sharing and other research and development \| program	3
G S K 2023 Amendment \| Related Party
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Deferred revenue			20,000,000.0		20,000,000.0		$ 20,000,000.0
Total revenue			$ 17,000	$ 0	$ 17,000	$ 0

Segment Information

6 Months Ended

Sep. 30, 2024

Segment Reporting [Abstract]

Segment Information

The Company currently operates in two reporting segments: (1) Consumer and Research Services, and (2) Therapeutics. The Consumer and Research Services segment consists of revenue and expenses from PGS and telehealth, as well as research services revenue and expenses from certain collaboration agreements (including the original GSK Agreement). The Therapeutics segment consists of revenues from the out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates under clinical development. Substantially all of the Company’s revenues are derived from the Consumer and Research Services segment. See Note 3, “Revenue — Revenue Recognition,” for additional information. There are no inter-segment sales.

Certain department expenses such as Finance, Legal, Regulatory and Supplier Quality, Corporate Communications, Corporate Development, and CEO Office are not reported as part of the reporting segments as reviewed by the CODM (as defined below). These amounts are included in Unallocated Corporate in the reconciliations below. The chief operating decision-maker (“CODM”) is the CEO. The CODM evaluates the performance of each segment based on

Adjusted EBITDA. Adjusted EBITDA is a non-GAAP financial measure that is defined as net income (loss) before net interest income (expense), net other income (expense), income tax expenses (benefit), depreciation and amortization, impairment charges, stock-based compensation expense, and other items that are considered unusual or not representative of underlying trends of the Company’s business, including but not limited to: litigation settlements, gains or losses on dispositions of subsidiaries, transaction-related costs, and cyber security incident expenses, net of probable insurance recoveries, if applicable for the periods presented.

Adjusted EBITDA is a key measure used by the Company’s management and Board of Directors to understand and evaluate the Company’s operating performance and trends, to prepare and approve the annual budget, and to develop short-term and long-term operating plans.

The Company’s revenue and Adjusted EBITDA by segment is as follows:


	Three Months Ended September 30,				Six Months Ended September 30,
	2024		2023		2024		2023
	(in thousands)
Segment Revenue: (1)
Consumer and Research Services	$	44,071	$	49,999	$	84,485	$	110,863
Total revenue	$	44,071	$	49,999	$	84,485	$	110,863
Segment Adjusted EBITDA:
Consumer and Research Services Adjusted EBITDA	$	(8,633)	$	(6,673)	$	(17,474)	$	(12,275)
Therapeutics Adjusted EBITDA	(11,975)		(26,224)		(24,392)		(57,363)
Unallocated Corporate	(12,804)		(12,156)		(26,708)		(25,215)
Total Adjusted EBITDA	$	(33,412)	$	(45,053)	$	(68,574)	$	(94,853)
Reconciliation of net loss to Adjusted EBITDA:
Net loss	$	(59,103)	$	(75,270)	$	(128,503)	$	(179,894)
Adjustments:
Interest income, net	(2,009)		(3,752)		(4,583)		(8,059)
Other (income) expense, net	(15)		(145)		4		(477)
Provision for (benefit from) income taxes	(41)		36		(41)		36
Depreciation and amortization	4,972		4,474		8,983		8,951
Amortization of acquired intangible assets	1,775		3,638		3,551		7,277

Stock-based compensation expense	19,486		23,741		41,063		74,840
Loss on disposition of Lemonaid Health Limited and transaction-related costs(2)	—		2,127		—		2,375
Litigation settlement cost	—		98		—		98

Cyber security incident expenses, net of probable insurance recoveries (3)	1,523		—		10,952		—
Total Adjusted EBITDA	$	(33,412)	$	(45,053)	$	(68,574)	$	(94,853)

(1)There was no Therapeutics revenue for the three and six months ended September 30, 2024 and 2023.

(2)Refer to Note 17, “Disposition of Subsidiary” for additional information.

(3)Refer to Note 11, “Cyber Security Incident” for additional information.

Customers accounting for 10% or more of segment revenues were as follows:


	Three Months Ended September 30,								Six Months Ended September 30,

	2024				2023				2024				2023

	(in thousands)
Consumer and Research Services Segment Revenue:
Customer C (1)(2)	$	11,586	26	%	$	13,040	26	%	$	19,163	23	%	$	22,751	21	%
Customer B (3)	*		*		*		*		*		*		$	11,753	11	%

•less than 10%

(1)Customer C is a reseller.

(2)Customer C revenues are primarily in the United States.

(3)Customer B revenues are in the U.K.

Revenue from customers by service and by geographical region can be found in the revenue recognition disclosures in Note 3, “Revenue.” Substantially all of the Company’s property and equipment, net of depreciation and amortization, was located in the United States during the periods presented. The reporting segments do not present total assets as they are not reviewed by the CODM when evaluating their performance.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

+ Details

Balance Sheet Components - Schedule of Prepaid Expense and Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Mar. 31, 2024
Balance Sheet Related Disclosures [Abstract]
Prepaid expenses	$ 12,894	$ 9,296
Insurance recovery receivable	22,633	2,188
Other receivables	1,751	3,563
Other current assets	2,372	1,794
Prepaid expenses and other current assets	$ 39,650	$ 16,841

Balance Sheet Components - Schedule of Amortization Expense of the Identified Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Mar. 31, 2024
Balance Sheet Related Disclosures [Abstract]
Remainder of 2025 (Remaining six months)	$ 3,960
2026	7,919
2027	6,769
2028	5,006
2029	3,175
Thereafter	2,466
Total estimated future amortization expense	$ 29,295	$ 33,255

Related Party Transactions	6 Months Ended
Related Party Transactions	Sep. 30, 2024
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions As described in Note 4, “Collaborations,” in July 2018, the Company and GSK entered into the original GSK Agreement, and there were transactions with GSK during the three months ended September 30, 2024 and 2023. At the time the original GSK Agreement was entered into, GSK also purchased shares of Series F-1 redeemable convertible preferred stock of 23andMe, Inc. These shares were converted into a like number of shares of 23andMe, Inc. Class B common stock immediately prior to the Merger and were exchanged pursuant to the share conversion ratio provided for in the Merger Agreement into shares of the Company’s Class B common stock. GSK had a 19.7% and 19.9% voting interest in the Company as of September 30, 2024 and March 31, 2024, respectively. The Anne Wojcicki Foundation, which subscribed for 125,000 shares of the Company’s Class A common stock in the PIPE investment in connection with the Merger, is affiliated with the Company’s CEO and therefore a related party. In January 2024, the Company entered into a research services agreement (the “TWF Agreement”) and related statement of work (the “initial SOW”) with the Troper Wojcicki Foundation (“TWF”) with the goal of expanding scientific knowledge in the field of lung cancer using the Company’s phenotype and genotype data to build large scale research cohorts. At the time, Susan Wojcicki was a director and officer of TWF, and a sibling of the Company’s CEO, Anne Wojcicki, and therefore the Company determined that TWF is a related party. The TWF Agreement has a term of five years through December 21, 2028. The fees under the initial SOW are $5.4 million, payable in installments over the term of the TWF Agreement, with certain payments being subject to the achievement of specified milestones. The Company recognized revenue from the TWF Agreement of $0.3 million and nil during the three months ended September 30, 2024 and 2023, respectively, and $0.5 million and nil during the six months ended September 30, 2024 and 2023, respectively. As of September 30, 2024 and March 31, 2024, the Company had deferred revenue of $1.7 million and $1.0 million, respectively, associated with the TWF Agreement.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

+ Details

Net Loss Per Share Attributable to Common Stockholders (Tables)

6 Months Ended

Sep. 30, 2024

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted

The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the periods presented:


	Three Months Ended September 30,								Six Months Ended September 30,
	2024				2023				2024				2023
	Class A		Class B		Class A		Class B		Class A		Class B		Class A		Class B
	(in thousands, except share and per share data)
Numerator:
Net loss attributable to common stockholders	$	(39,822)	$	(19,281)	$	(48,699)	$	(26,571)	$	(85,949)	$	(42,554)	$	(115,546)	$	(64,348)
Denominator:
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted	17,194,568		8,325,090		15,361,280		8,381,634		16,822,770		8,329,218		15,048,689		8,380,911
Net loss per share attributable to common stockholders:
Net loss per share attributable to common stockholders, basic and diluted	$	(2.32)	$	(2.32)	$	(3.17)	$	(3.17)	$	(5.11)	$	(5.11)	$	(7.68)	$	(7.68)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share


	Three and Six Months Ended September 30,
	2024	2023
Outstanding stock options	3,134,850	3,781,897
Unvested restricted stock units	3,401,997	2,036,251
Shares subject to vesting	—	15,066
ESPP	325,939	283,111
Total	6,862,786	6,116,325

Organization and Description of Business (Details)	6 Months Ended
Organization and Description of Business (Details)	Sep. 30, 2024 reportable_segment	Oct. 29, 2024 independent_director	Sep. 17, 2024 nonemployee_Director	Jul. 29, 2024 $ / shares
Business Acquisition [Line Items]
Number of non-employee resigning directors \| nonemployee_Director			7
Number of reporting segments \| reportable_segment	2
Subsequent Event
Business Acquisition [Line Items]
Number of independent directors appointed \| independent_director		3
Preliminary Proposal
Business Acquisition [Line Items]
Business acquisition, share price (in usd per share) \| $ / shares				$ 0.40

Condensed Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Thousands	6 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Accounts receivable, net related party	$ 2,878	$ 396
Accounts payable, related party	(5,063)	(3,951)
Accrued expenses and other current liabilities, related party	1,899	(5,674)
Deferred revenue, related party	(5,076)	(22,237)
Related Party
Accounts receivable, net related party	1	19
Accounts payable, related party	(3,809)	(3,186)
Accrued expenses and other current liabilities, related party	(4,822)	4,993
Deferred revenue, related party	$ 661	$ (11,753)

Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands

3 Months Ended

6 Months Ended

Sep. 30, 2024

Jun. 30, 2024

Sep. 30, 2023

Jun. 30, 2023

Sep. 30, 2024

Sep. 30, 2023

Numerator:

Net loss attributable to common stockholders

$ (59,103)

$ (69,400)

$ (75,270)

$ (104,624)

$ (128,503)

$ (179,894)

Denominator:

Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares)

^[1]

25,519,658

23,742,914

25,151,988

23,429,600

Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares)

^[1]

25,519,658

23,742,914

25,151,988

23,429,600

Net loss per share attributable to common stockholders:

Net loss per share attributable to common stockholders, basic (in usd per share)

^[1]

$ (2.32)

$ (3.17)

$ (5.11)

$ (7.68)

Net loss per share attributable to common stockholders, diluted (in usd per share)

^[1]

$ (2.32)

$ (3.17)

$ (5.11)

$ (7.68)

Class A Common Stock

Numerator:

Net loss attributable to common stockholders

$ (39,822)

$ (48,699)

$ (85,949)

$ (115,546)

Denominator:

Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares)

17,194,568

15,361,280

16,822,770

15,048,689

Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares)

17,194,568

15,361,280

16,822,770

15,048,689

Net loss per share attributable to common stockholders:

Net loss per share attributable to common stockholders, basic (in usd per share)

$ (2.32)

$ (3.17)

$ (5.11)

$ (7.68)

Net loss per share attributable to common stockholders, diluted (in usd per share)

$ (2.32)

$ (3.17)

$ (5.11)

$ (7.68)

Class B Common Stock

Numerator:

Net loss attributable to common stockholders

$ (19,281)

$ (26,571)

$ (42,554)

$ (64,348)

Denominator:

Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares)

8,325,090

8,381,634

8,329,218

8,380,911

Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares)

8,325,090

8,381,634

8,329,218

8,380,911

Net loss per share attributable to common stockholders:

Net loss per share attributable to common stockholders, basic (in usd per share)

$ (2.32)

$ (3.17)

$ (5.11)

$ (7.68)

Net loss per share attributable to common stockholders, diluted (in usd per share)

$ (2.32)

$ (3.17)

$ (5.11)

$ (7.68)

[1]	Amounts have been adjusted to reflect the reverse stock split that became effective on October 16, 2024. Refer to Note 2, “Summary of Significant Accounting Policies” and Note 19, “Subsequent Events,” for further information about the reverse stock split.

Leases - Additional Information (Details)	3 Months Ended		6 Months Ended
Leases - Additional Information (Details)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 16, 2024 USD ($) ft²
Lessee Lease Description [Line Items]
Lease, option to extend, term	7 years		7 years
Area of real estate property \| ft²					17,312
Lessor, operating lease, term of contract					4 years
Lessor, operating lease, payment to be received					$ 3,200,000
Sublease income	$ 30,000	$ 0	$ 30,000	$ 0
Operating lease cost	3,300,000	3,400,000	6,700,000	6,800,000
Variable lease cost	$ 1,400,000	$ 1,200,000	$ 2,900,000	$ 2,500,000
Minimum
Lessee Lease Description [Line Items]
Operating lease, contract period	1 year 3 months 18 days		1 year 3 months 18 days
Maximum
Lessee Lease Description [Line Items]
Operating lease, contract period	6 years 9 months 18 days		6 years 9 months 18 days

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Income tax expense	$ (41)	$ 36	$ (41)	$ 36

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-10

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Subparagraph (a)
-SubTopic 20
-Topic 740
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482659/740-20-45-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-SubTopic 10
-Topic 235
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

+ Details

Equity Incentive Plans and Stock-Based Compensation - Schedule of Weighted Average Black-Scholes Assumptions (Details)	3 Months Ended		6 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
A And R ESPP
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected volatility range, minimum	76.00%	67.00%	76.00%	67.00%
Expected volatility range, maximum	77.00%	73.00%	77.00%	73.00%
Expected weighted-average volatility	76.00%	70.00%	76.00%	70.00%
Risk-free interest rate, minimum	4.40%	5.40%	4.40%	5.40%
Risk-free interest rate, maximum	4.80%	5.50%	4.80%	5.50%
Outstanding stock options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected volatility range, minimum	75.00%	78.00%	75.00%	78.00%
Expected volatility range, maximum	75.00%	79.00%	75.00%	79.00%
Expected weighted-average volatility	75.00%	79.00%	75.00%	79.00%
Risk-free interest rate, minimum	3.50%	4.40%	3.50%	3.60%
Risk-free interest rate, maximum	3.50%	4.40%	3.50%	4.40%
Minimum \| A And R ESPP
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected term (years)	6 months	6 months	6 months	6 months
Expected dividend yield	0.00%	0.00%	0.00%	0.00%
Minimum \| Outstanding stock options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected term (years)	6 years	5 years 9 months 18 days	6 years	5 years 9 months 18 days
Expected dividend yield	0.00%	0.00%	0.00%	0.00%
Maximum \| A And R ESPP
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected term (years)	1 year	1 year	1 year	1 year
Expected dividend yield	0.00%	0.00%	0.00%	0.00%
Maximum \| Outstanding stock options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected term (years)	6 years	6 years	6 years	6 years
Expected dividend yield	0.00%	0.00%	0.00%	0.00%

Disposition of Subsidiary	6 Months Ended
Disposition of Subsidiary	Sep. 30, 2024
Disposition of Subsidiary [Abstract]
Disposition of Subsidiary	Disposition of Subsidiary Disposition of Lemonaid Health Limited On August 1, 2023, the Company completed the sale of Lemonaid Health Limited, its wholly-owned, indirect U.K. subsidiary. Lemonaid Health Limited was not a significant subsidiary, and the disposition of Lemonaid Health Limited did not constitute a strategic shift that would have a major effect on the Company’s operations or financial results. As a result, the results of operations for Lemonaid Health Limited were not reported as discontinued operations under the guidance of ASC 205 “Presentation of Financial Statements.” During the three and six months ended September 30, 2023, the Company recorded $2.1 million and $2.4 million, respectively, of loss on the disposition of Lemonaid Health Limited and transaction-related costs within general and administrative expenses. There were no charges incurred during the three and six months ended September 30, 2024.

Net Loss Per Share Attributable to Common Stockholders - Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details) - Class A Common Stock - shares	3 Months Ended		6 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Earnings Per Share Basic [Line Items]
Antidilutive securities excluded from computation of diluted net loss per share (in shares)	6,862,786	6,116,325	6,862,786	6,116,325
ESPP
Earnings Per Share Basic [Line Items]
Antidilutive securities excluded from computation of diluted net loss per share (in shares)	325,939	283,111	325,939	283,111
Outstanding stock options
Earnings Per Share Basic [Line Items]
Antidilutive securities excluded from computation of diluted net loss per share (in shares)	3,134,850	3,781,897	3,134,850	3,781,897
Unvested restricted stock units
Earnings Per Share Basic [Line Items]
Antidilutive securities excluded from computation of diluted net loss per share (in shares)	3,401,997	2,036,251	3,401,997	2,036,251
Shares subject to vesting
Earnings Per Share Basic [Line Items]
Antidilutive securities excluded from computation of diluted net loss per share (in shares)	0	15,066	0	15,066

Related Party Transactions (Details) - USD ($) $ in Thousands		1 Months Ended	3 Months Ended			6 Months Ended
	Feb. 04, 2021	Jan. 31, 2024	Sep. 30, 2024	Jun. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Mar. 31, 2024
Related Party Transaction [Line Items]
Total revenue			$ 44,071		$ 49,999	$ 84,485	$ 110,863
Related Party \| The Anne Wojcicki Foundation \| Class A Common Stock
Related Party Transaction [Line Items]
Subscription shares issued (in shares)	125,000
Related Party \| Glaxo Smith Kline Plc Collaboration Agreement
Related Party Transaction [Line Items]
Voting interest percentage				19.90%		19.70%
Related Party \| TWF Agreement
Related Party Transaction [Line Items]
Total revenue			300		$ 0	$ 500	$ 0
Related Party \| TWF Agreement \| Troper Wojcicki Foundation
Related Party Transaction [Line Items]
TWF agreement, period		5 years
Deferred revenue for customer services		$ 5,400	$ 1,700			$ 1,700		$ 1,000

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Non-cancelable Purchase Obligations In the normal course of business, the Company enters into agreements containing non-cancelable purchase commitments for goods or services with various parties, which include agreements to purchase goods or services that are enforceable and legally binding to the Company. Recognition of purchase obligations occurs when products or services are delivered to the Company, generally within accounts payable, or accrued and other current liabilities. As of September 30, 2024, the Company had a total of $59.6 million in outstanding non-cancelable purchase obligations with a term of 12 months or longer that have not been recognized on its balance sheet. Legal Matters Cyber Security Incident On October 10, 2023, the Company reported that certain information was accessed from individual 23andMe.com accounts without the account users’ authorization (the “Incident”). As a result of the Incident, multiple class action claims have been filed against the Company in federal and state courts in California, as well as in other U.S. and international jurisdictions, and the Company has received demand letters from attorneys purporting to represent customers seeking arbitration claims. The Company is also responding to inquiries from various governmental officials and agencies. The federal class action claims were coordinated for pretrial proceedings by the Multidistrict Litigation Panel, and on June 5, 2024, co-lead plaintiffs’ counsel were appointed. On July 15, 2024, the Company reached an agreement in principle to settle the putative class action lawsuits currently pending in the U.S. District Court for the Northern District of California (the “Court”). The parties executed a confidential settlement term sheet on July 29, 2024, which contemplated an aggregate cash payment by the Company of $30.0 million to settle all claims brought on behalf of all persons in the United States whose personal information was impacted by the Incident. In addition, the Company agreed to document various business practice initiatives relating to cybersecurity and provide customers with the option to enroll in a privacy and monitoring service for three years. The Company subsequently reached an agreement with the plaintiffs on all material terms, including payment of $30.0 million (the “Settlement Agreement”). On September 12, 2024, plaintiffs filed a motion asking the Court for preliminary approval of the Settlement Agreement, and the motion was considered at a court hearing on October 29, 2024. On October 29, 2024, the Court deferred the motion for preliminary approval of the Settlement Agreement and asked the parties to provide additional information by November 12, 2024. The Settlement Agreement, if approved by the Court, will provide for a full release of all claims arising out of the Incident by the class action members (who do not opt out) against the Company. The proposed settlement is not an admission of fault or wrongdoing by the Company; the Company believes that a resolution of these claims at this time is in the best interest of the Company and its stockholders given the costs and risks inherent in litigation. During the three months ended September 30, 2024, the Company recognized an additional $1.5 million in expenses related to the Incident. During the six months ended September 30, 2024, the Company recognized $11.0 million in net expenses related to the incident primarily consisting of $33.1 million legal fees incurred and the proposed settlement amount, partially offset by probable insurance recoveries of $22.1 million as of September 30, 2024, within general and administrative expense in the condensed consolidated statements of operations and comprehensive loss. As of September 30, 2024, the Company had accrued a payable related to the settlement of $30.0 million, and insurance recoveries of $22.6 million were included in prepaid and other current assets in the condensed consolidated balance sheets. Indemnification The Company enters into indemnification provisions under agreements with other companies in the ordinary course of business, including, but not limited to, collaborators, landlords, vendors, and contractors. Pursuant to these arrangements, the Company agrees to indemnify, defend, and hold harmless the indemnified party for certain losses suffered or incurred by the indemnified party as a result of the Company’s activities. The maximum potential amount of future payments the Company could be required to make under these agreements is not determinable. As of the date of this filing, the Company has never incurred costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the Company believes that the fair value of these provisions is not material. The Company maintains insurance, including commercial general liability insurance and product liability insurance, to offset certain potential liabilities under these indemnification provisions. In addition, the Company indemnifies its officers, directors, and certain key employees against claims made with respect to matters that arise while they are serving in their respective capacities as such, subject to certain limitations set forth under applicable law, the Company’s Bylaws, and applicable indemnification agreements. As of September 30, 2024, the Company was not aware of any known events or circumstances that have resulted in a material claim related to these indemnification obligations.

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Sep. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Sep. 30, 2023	Sep. 30, 2023
Revenue	$ 49,999	$ 110,863
Cost of revenue	28,270	58,453
Research and development	54,588	116,917
Related Party
Revenue	1,082	11,753
Cost of revenue	20	295
Research and development	$ 4,907	$ 8,208

- Definition

The aggregate cost of goods produced and sold and services rendered during the reporting period.

Summary of Significant Accounting Policies

6 Months Ended

Sep. 30, 2024

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Basis of Presentation and Principle of Consolidation

The Company’s unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and include the accounts of the Company and its wholly owned subsidiaries, and variable interest entities in which it holds a controlling financial interest. All intercompany accounts and transactions have been eliminated in consolidation.

For the three and six months ended September 30, 2024 and 2023, the Company’s operations were primarily in the United States. The Company had immaterial operations in the United Kingdom (“U.K.”) prior to the disposition of its U.K. subsidiary on August 1, 2023.

There have been no material changes to the Company’s significant accounting policies during the six months ended September 30, 2024, as compared to the audited consolidated financial statements in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2024 filed with the SEC on May 30, 2024 (the “Fiscal 2024 Form 10-K”).

Change in Capital Structure

As described more fully in Note 19, “Subsequent Events,” effective October 16, 2024, the Company effected a one-for-twenty reverse stock split of all of its issued and outstanding shares of Class A common stock and Class B common stock (the “Reverse Stock Split”). All share and per share amounts presented in the unaudited condensed consolidated financial statements and accompanying notes, including, but not limited to, shares issued and outstanding, dollar amounts of common stock, additional paid-in capital, earnings/(loss) per share, and options, have been retroactively adjusted for all periods presented in order to reflect this change in capital structure. There were no changes to the total numbers of authorized shares of Class A common stock and Class B common stock or their respective par values per share as a result of this change.

Unaudited Interim Condensed Consolidated Financial Information

The accompanying interim condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements (the “condensed consolidated financial statements”) have been prepared in accordance with GAAP applicable to interim financial statements. These financial statements are presented in accordance with the rules and regulations of the SEC and do not include all disclosures normally required in annual consolidated financial statements prepared in accordance with GAAP. As such, the information included herein should be read in conjunction with the consolidated financial statements and accompanying notes as of and for the fiscal year ended March 31, 2024 (the “audited consolidated financial statements”) that were included in the Fiscal 2024 Form 10-K. In management’s opinion, the unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements, which include only normal recurring adjustments, necessary for a fair statement of the Company’s financial position as of September 30, 2024 and its condensed consolidated results of operations and cash flows for the six months ended September 30, 2024 and 2023. The results of operations for the three and six months ended September 30, 2024 are not necessarily indicative of the results expected for the year ending March 31, 2025 or any other future interim or annual periods, due to among other factors, the seasonal nature of the business.

Fiscal Year

The Company’s fiscal year ends on March 31. References to fiscal 2025 refer to the fiscal year ending March 31, 2025 and references to fiscal 2024 and fiscal 2023 refer to the fiscal years ended March 31, 2024 and March 31, 2023, respectively.

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities and the related disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period and the accompanying notes. Significant items subject to such estimates and assumptions include, but are not limited to the determination of standalone selling price for various performance obligations; the estimated expected benefit period for the rate and recognition pattern of breakage revenue for

purchases where a saliva collection kit (“kit”) is never returned for processing; the capitalization and estimated useful life of internal use software; the useful life of long-lived assets; fair value of intangible assets acquired in business combinations; the incremental borrowing rate for operating leases; stock-based compensation including the determination of the fair value of stock options and annual incentive bonuses payable in the form of restricted stock units (“RSUs”); the assumptions used in going concern assessments; and the valuation of deferred tax assets and uncertain tax positions. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that it believes are reasonable under the circumstances, including assumptions as to future events. Actual results could differ from these estimates, and such differences could be material to the condensed consolidated financial statements.

The Company is not aware of any specific event or circumstance that would require revisions to estimates, updates to judgments, or adjustments to the carrying value of assets or liabilities. These estimates may change, as new events occur and/or additional information is obtained, and will be recognized in the condensed consolidated financial statements as soon as they become known.

Concentration of Supplier Risk

Certain of the raw materials, components, and equipment associated with the deoxyribonucleic acid (“DNA”) microarrays and kits used by the Company in the delivery of its services are available only from third-party suppliers. The Company also relies on a third-party laboratory service for the processing of its customer samples. Shortages and slowdowns could occur in these essential materials, components, equipment, and laboratory services due to an interruption of supply or increased demand in the industry. If the Company were unable to procure certain materials, components, equipment, or laboratory services at acceptable prices, it would be required to reduce its laboratory operations, which could have a material adverse effect on its results of operations.

A single supplier accounted for 100% of the Company’s total purchases of microarrays, and a separate single supplier accounted for 100% of the Company’s total purchases of kits for the three and six months ended September 30, 2024 and 2023. One laboratory service provider accounted for 100% of the Company’s processing of customer samples for the three and six months ended September 30, 2024 and 2023.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to a concentration of credit risk include cash, cash equivalents, and accounts receivable. The Company maintains a majority of its cash and cash equivalents with a single high-quality financial institution, the composition and maturities of which are regularly monitored by the Company. The Company’s revenue and accounts receivable are derived primarily from the United States. See Note 3, “Revenue,” for additional information regarding geographical disaggregation of revenue. The Company grants credit to its customers in the normal course of business, performs credit evaluations of its significant customers on an as-needed basis, and does not require collateral. Concentrations of credit risk are limited as the Company’s trade receivables are primarily related to third parties, which collect its credit card receivables, and large multinational corporations. The Company regularly monitors the aging of accounts receivable balances.

Significant customer information is as follows:


	September 30, 2024		March 31, 2024
Percentage of accounts receivable:
Customer C(1)	10	%	59	%
Customer F	55	%	—	%
Customer I	—	%	30	%
Customer J	14	%	*
Customer K	17	%	*

•less than 10%

(1)Customer C is a reseller.


	Three Months Ended September 30,				Six Months Ended September 30,
	2024		2023		2024		2023
Percentage of revenue:
Customer C(1)	26	%	26	%	23	%	21	%
Customer B	*		*		*		11	%

•less than 10%

(1)Customer C is a reseller.

Cash, Cash Equivalents and Restricted Cash

Cash consists of bank deposits held at financial institutions. Cash in U.S. banks is insured to the extent defined by the Federal Deposit Insurance Corporation. Cash equivalents consist primarily of short-term money market funds. The Company maintains certain cash amounts restricted as to its withdrawal or use, which are related to letters of credit in connection with the Company's Sunnyvale operating lease agreement and the Company’s credit card processor, as well as collateral held against the Company’s corporate credit cards. The Company held total restricted cash of $10.5 million and $8.4 million as of September 30, 2024 and March 31, 2024, respectively. The increase in restricted cash related to a new letter of credit entered into by the Company in April 2024 as collateral related to the Company’s credit card processor. On November 1, 2024, there was a $3.5 million increase in the restricted cash balances related to an amended letter of credit entered into by the Company as collateral related to the Company’s credit card processor.

Escrow Related to Acquisition

On November 1, 2021, the Company completed its acquisition of Lemonaid Health, and upon the acquisition closing date, funds were placed in escrow to cover a potential purchase price adjustment and to secure the indemnification obligations of the former equity holders of Lemonaid Health. In May 2023, $6.0 million of the escrow amount was released. The remaining escrow amount of $6.2 million was released during the first quarter of fiscal 2025. Accordingly, the entire escrow amount has been released.

Liquidity and Going Concern

Going Concern

The unaudited interim condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates continuity of operations, realization of assets, and the satisfaction of liabilities in the normal course of business.

In accordance with Subtopic 205-40, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that the unaudited interim condensed consolidated financial statements included in this report are issued.

The Company has incurred significant operating losses as reflected in its accumulated deficit and negative cash flows from operations. As of September 30, 2024, the Company had an accumulated deficit of $2.3 billion, and cash and cash equivalents of $126.6 million. The Company will need additional liquidity to fund its necessary expenditures and financial commitments for 12 months after the date that the unaudited interim condensed consolidated financial statements included in this report are issued. The Company has determined that, as of the filing date of this report, there is substantial doubt about the Company’s ability to continue as a going concern.

To improve its financial condition and liquidity position, the Company is working to execute its business plan, manage ongoing operational expenses, and implement cost-cutting measures, as well as raising additional capital. See Note 19, “Subsequent Events,” for additional details. The Company’s ability to continue as a going concern, however, is contingent upon the Company’s ability to successfully implement its operational and financial plans, and if the Company fails to do so and/or is unable to raise sufficient capital or consummate a strategic transaction, it could be forced to modify or cease operations. While the Company believes in the viability of its strategy, there are numerous risks and uncertainties that may prevent, and there can be no assurances regarding, the successful implementation of the Company’s operational and financial plans and/or the consummation of any transactions. See Note 1, “Organization and Description of Business” for additional details.

The unaudited interim condensed consolidated financial statements do not reflect any adjustments pertaining to the recoverability and classification of assets or the amount and classification of liabilities or any other adjustments that would be necessary if the Company were unable to continue as a going concern.

Nasdaq Deficiency Minimum Bid Price

On November 10, 2023, the Company received a deficiency letter (the “First Nasdaq Letter”) from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that it was not in compliance with Nasdaq Listing Rule 5450(a)(1), which requires the Company to maintain a minimum bid price of at least $1.00 per share for continued listing on The Nasdaq Global Select Market (the “Minimum Bid Requirement”). The Company’s failure to comply with the Minimum Bid Requirement was based on its Class A common stock per share price being below the $1.00 threshold for a period of 30 consecutive trading days. Pursuant to the First Nasdaq Letter, the Company had an initial 180 calendar days from the date of the First Nasdaq Letter to regain compliance. The Company did not regain compliance during the initial compliance period.

On May 9, 2024, the Company received a notification letter from the Staff notifying the Company that it had been granted an additional 180 days, or until November 4, 2024, to regain compliance with the Minimum Bid Requirement, based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on The Nasdaq Capital Market with the exception of the bid price requirement, and the Company’s written notice of its intention to cure the deficiency during the second compliance period. In order to be eligible to receive the second compliance period, the Company applied to have its Class A common stock transferred from the Nasdaq Global Select Market to the Nasdaq Capital Market.

In connection with the foregoing, on July 16, 2024, the Company filed a Definitive Proxy Statement on Schedule 14A with the SEC in connection with the Company’s 2024 Annual Meeting of Stockholders, which was held on August 26, 2024 (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders, by an affirmative vote of the holders of at least two-thirds (67%) of the voting power of the outstanding shares of the Company’s Class A common stock and Class B common stock voting together as a single class, approved a proposal authorizing the Company’s Board of Directors, in its discretion, to effect a reverse stock split of the Company’s outstanding shares of Class A common stock and Class B common stock, respectively, by a ratio of not less than one-for-five and not more than one-for-thirty, with the exact ratio to be set within this range by the Company’s Board of Directors in its sole discretion. On October 7, 2024, the Company’s Board of Directors approved the Reverse Stock Split at a ratio of one-for-twenty. The Reverse Stock Split became effective as of 12:01 a.m. Eastern Time on October 16, 2024, and on October 30, 2024, the Company regained compliance with the Minimum Bid Requirement. See Note 19, “Subsequent Events,” for additional details.

Nasdaq Deficiency Independent Directors

On September 18, 2024, the Company received a deficiency letter from the Staff, notifying the Company that the Company was not in compliance with Nasdaq Listing Rule 5605 (the “Second Nasdaq Letter”). Specifically, as a result of the Resignations, the Company was no longer in compliance with the following (collectively, the “Corporate Governance Requirements”):

•Nasdaq Listing Rule 5605(b), which requires, among other things, that a majority of the Company’s Board of Directors be comprised of Independent Directors (as defined in Nasdaq Listing Rule 5605(a)(2));

•Nasdaq Listing Rule 5605(c), which requires, among other things, that the Company have an Audit Committee that has at least three members, each of whom must (i) be an Independent Director, (ii) meet the criteria for independence set forth in Rule 10A-3(b)(1) under the Securities Exchange Act of 1934, as amended, (iii) not have participated in the preparation of the financial statements of the Company or any current subsidiary of the Company at any time during the past three years, and (iv) be able to read and understand fundamental financial statements;

•Nasdaq Listing Rule 5605(d), which requires, among other things, that the Company have a Compensation Committee that has at least two members, each of whom must be an Independent Director; and

•Nasdaq Listing Rule 5605(e), which requires, among other things, that the Company have Independent Director oversight of director nominations.

Pursuant to the Second Nasdaq Letter, the Company had until October 3, 2024 to submit a plan to regain compliance with the Corporate Governance Requirements (the “Plan”) for the Staff’s review. The Company submitted the

Plan to the Staff on September 26, 2024, and on October 30, 2024, the Company regained compliance with the Corporate Governance Requirements. See Note 19, “Subsequent Events” for additional details.

Recently Issued Accounting Pronouncements Not Yet Effective

In November 2023, the Financial Accounting Standard Board (“FASB”) issued Accounting Standard Updated (“ASU”) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires disclosure of incremental segment information on an annual and interim basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and requires retrospective application to all prior periods presented in the financial statements. Early adoption is permitted. The Company is currently evaluating the impacts of the new standard.

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which expands disclosures in an entity’s income tax rate reconciliation table and income taxes paid information. This ASU is effective for fiscal years beginning after December 15, 2024 and may be adopted on a prospective or retrospective basis. Early adoption is permitted. The Company is currently evaluating the impacts and method of adoption.

In November 2024, the FASB issued ASU No. 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures, which requires more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation, amortization, and depletion) included in certain expense captions presented on the face of the income statement. This ASU is effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact of this new standard.

Restructuring

6 Months Ended

Sep. 30, 2024

Restructuring and Related Activities [Abstract]

Restructuring

In June 2023, the Company approved a reduction in force intended to restructure and align strategically its workforce with the Company’s strategy and to reduce the Company’s operating costs, primarily in the Consumer and Research Services segment. Subsequently in August 2023, the Company approved another reduction in force primarily intended to restructure and strategically align the Therapeutics segment’s workforce. On August 1, 2024, the Board of Directors of the Company determined that it was in the best interests of the Company and its stockholders to cease operations of the Therapeutics Discovery portion of the Company’s Therapeutics segment, effective August 9, 2024. During the three and six months ended September 30, 2024, the Company recorded restructuring charges of $2.2 million within restructuring and other charges in the condensed consolidated statements of operations, of which $1.9 million was related to cash severance payments and benefits continuation in connection with this reduction in force. During the three and six months ended September 30, 2023, the Company recorded restructuring charges of $2.7 million and $6.9 million, respectively, within restructuring and other charges in the condensed consolidated statements of operations, of which $2.7 million and $6.3 million, respectively, was related to cash severance payments and benefits continuation.

The following table shows the total amount incurred and accrued related to one-time employee termination benefits:


	One-Time Employee Termination Benefits
	(in thousands)
Accrued restructuring costs included in accrued expenses and other current liabilities as of March 31, 2024	$	22
Restructuring charges incurred during the period	2,242
Amounts paid during the period	(2,017)
Accrued restructuring costs included in accrued expenses and other current liabilities as of September 30, 2024	$	247

The Company does not expect to incur any further material expenses in connection with the Therapeutics Discovery RIF.

Revenue

6 Months Ended

Sep. 30, 2024

Revenue from Contract with Customer [Abstract]

Revenue

Disaggregation of Revenue

The following table presents revenue by category:


	Three Months Ended September 30,								Six Months Ended September 30,
	2024				2023				2024				2023
	Amount		% of Revenue		Amount		% of Revenue		Amount		% of Revenue		Amount		% of Revenue

	(in thousands, except percentages)
Point in Time (1)
Personal genome service (“PGS”)	$	27,652	63	%	$	34,202	68	%	$	52,049	62	%	$	65,961	59	%
Telehealth	4,890		11	%	6,872		14	%	9,929		12	%	15,157		14	%
Consumer services	32,542		74	%	41,074		82	%	61,978		74	%	81,118		73	%
Research services	—		—	%	—		—	%	344		—	%	2,353		2	%
Total	$	32,542	74	%	$	41,074	82	%	$	62,322	74	%	$	83,471	75	%

Over Time (1)
PGS	$	9,515	22	%	$	5,400	11	%	$	17,624	20	%	$	10,670	10	%
Telehealth	1,533		3	%	2,184		4	%	3,141		4	%	4,423		4	%
Consumer services	11,048		25	%	7,584		15	%	20,765		24	%	15,093		14	%
Research services	481		1	%	1,341		3	%	1,398		2	%	12,299		11	%
Total	$	11,529	26	%	$	8,925	18	%	$	22,163	26	%	$	27,392	25	%

Revenue by Category (1)
PGS	$	37,167	84	%	$	39,602	79	%	$	69,673	82	%	$	76,631	69	%
Telehealth	6,423		15	%	9,056		18	%	13,070		16	%	19,580		18	%
Consumer services	43,590		99	%	48,658		97	%	82,743		98	%	96,211		87	%
Research services	481		1	%	1,341		3	%	1,742		2	%	14,652		13	%
Total	$	44,071	100	%	$	49,999	100	%	$	84,485	100	%	$	110,863	100	%

(1)There was no Therapeutics revenue for the three and six months ended September 30, 2024 and 2023.

The following table summarizes revenue by region based on the shipping address of customers:


	Three Months Ended September 30,								Six Months Ended September 30,
	2024				2023				2024				2023
	Amount		% of Revenue		Amount		% of Revenue		Amount		% of Revenue		Amount		% of Revenue

	(in thousands, except percentages)
United States	$	38,671	88	%	$	42,185	84	%	$	73,956	88	%	$	85,511	77	%
United Kingdom	1,968		4	%	4,163		8	%	4,092		5	%	18,518		17	%
Canada	2,402		5	%	2,558		5	%	4,417		5	%	4,728		4	%
Other regions	1,030		3	%	1,093		3	%	2,020		2	%	2,106		2	%
Total	$	44,071	100	%	$	49,999	100	%	$	84,485	100	%	$	110,863	100	%

Breakage Revenue

The Company sells through multiple channels, including direct-to-consumer via the Company’s website and through online retailers. If the customer does not return the kit for processing, services cannot be completed by the Company, potentially resulting in unexercised rights (“breakage”) revenue. The Company recognized breakage revenue from unreturned kits of $5.4 million and $4.3 million for the three months ended September 30, 2024 and 2023, respectively, and $9.4 million and $8.9 million for the six months ended September 30, 2024 and 2023, respectively.

Contract Balances

Accounts receivable are recorded when the right to consideration becomes unconditional. Contract assets include amounts associated with contractual rights related to consideration for performance obligations in the Company's Research Services contracts and are included in prepaid expenses and other current assets on the condensed consolidated balance sheets. The amount of contract assets was immaterial as of September 30, 2024 and March 31, 2024.

Contract liabilities consist of deferred revenue. As of September 30, 2024 and March 31, 2024, deferred revenue for consumer services was $47.2 million and $52.3 million, respectively. Of the $52.3 million of deferred revenue for consumer services as of March 31, 2024, the Company recognized $10.8 million and $32.4 million as revenue during the three and six months ended September 30, 2024, respectively.

As of September 30, 2024 and March 31, 2024, deferred revenue for research services was $22.6 million and $22.5 million, respectively. As of September 30, 2024 and March 31, 2024, deferred revenue for research services included $21.7 million and $21.0 million, respectively, of related party deferred revenue. Of the $22.5 million of deferred revenue for research services as of March 31, 2024, the Company recognized $0.4 million and $1.4 million as revenue during the three and six months ended September 30, 2024, respectively, which included related party revenue of $0.3 million and $0.5 million for the three and six months ended September 30, 2024, respectively.

Remaining Performance Obligations

The transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes deferred revenue and amounts that are expected to be billed and recognized as revenue in future periods. The Company has utilized the practical expedient available under ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”) to not disclose the value of unsatisfied performance obligations for PGS and telehealth as those contracts have an expected length of one year or less. As of September 30, 2024, the aggregate amount of the transaction price allocated to remaining performance obligations for research services was $26.7 million. The Company expects to recognize revenue of approximately 86% of this amount over the next 12 months and the remainder thereafter. During the three and six months ended September 30, 2024 and 2023, revenue recognized for performance obligations satisfied in prior periods were immaterial.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-9

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-15

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-13

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org/606/tableOfContent

+ Details